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Abstract 
 
Introduction: The discovery of the endothelium as a regulator of vascular tone, and 
the subsequent discovery of nitric oxide (NO) as the major endothelium-derived 
relaxing factor (EDRF), has opened up vast possibilities in the continued efforts to 
prevent and manage cardiovascular disease. Endothelial dysfunction (ED) is defined 
as reduced NO bioavailability and hence the reduced ability of the endothelium to 
maintain vascular homeostasis. ED represents the first, reversible step in the 
initiation of atherosclerotic disease and is thus regarded as a strong predictive tool of 
ischaemic heart disease (IHD). ED and its underlying mechanisms have been largely 
under-investigated in myocardial capillary-derived endothelial cells (cardiac 
microvascular endothelial cells, CMECs), and this study aimed to address this gap in 
the literature. Oleanolic acid (OA) is a bioactive triterpenoid derived from leaf 
extracts of African medicinal plants such as Syzigium cordatum (Water berry tree), 
and has been reported to elicit vasodilatory, hypoglycaemic and hypolipidaemic 
properties. However its effects particularly on CMECs and its putative role in 
reversing ED remain unclear, and this study aimed to investigate such effects. 
 
Aims: The aims of this study were to: (1) Establish an in vitro model of ED in 
cultured myocardial capillary-derived CMECs by developing protocols for the 
induction of ED. (2) Asses ED induction by measurement of the following 
biomarkers: (i) intracellular NO production, (ii)  superoxide (O2
-) production,             
(iii) nitrotyrosine expression and (iv) NADPH oxidase expression. (3) Investigate 
underlying cellular mechanisms of our ED model by measuring and comparing 
eNOS and PKB/Akt expression and activation in control and dysfunctional CMECs. 
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(4) Investigate the effects of OA derived from leaf extracts obtained from Syzigium 
cordatum (Hochst.) [Myrtaceace], in both control and dysfunctional CMECs.  
 
Methods: (1) To induce ED, hyperglycaemia and inflammation were simulated by 
incubation with 25 mM glucose (24 hours) and 1 ng/ml TNF-α (24 hours) or 5 ng/ml 
TNF-α (6 and 24 hours) respectively. Reduced intracellular NO production was used 
as the main indicator of ED. NO production and cell viability were quantified by 
FACS analysis of the fluorescent probes, DAF-2/DA and propidium iodide (PI) / 
Annexin V respectively. Cellular mechanisms were investigated by measurement of 
O2
- levels via FACS analysis of DHE fluorescence, and measurement of total and 
activated PKB / Akt and eNOS, p22-phox, nitrotyrosine expression via Western 
blotting. (2) Effects of OA on CMECs were investigated by pre-treatment with 30 or 
40 µM OA for 5 and 20 min followed by NO production and cell viability 
measurements. To investigate the effects of OA on ED, CMECs were pre-treated 
with 40 µM OA 1 hour prior ED induction followed by NO, cell viability, and eNOS 
expression / activation measurements.  
 
Results: (1) 25 mM glucose (24hours), 1 ng/ml TNF-α (24 hours) and 5 ng/ml TNF-α 
(6 hours) failed to induce ED as verified by an increase in NO production in the 
treated cells. A model of ED was successfully achieved by incubating CMECs with   
5 ng/ml TNF-α (24 hours), as verified by a significant decrease in NO production. 
Investigations into cellular mechanisms underlying our TNF-α-induced ED model, 
showed that activated eNOS and PKB / Akt levels were reduced. Furthermore, O2
- 
levels remained unchanged, however p22-phox (NADPH) expression was 
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significantly increased suggesting oxidative stress. Nitrotyrosine levels (an oxidative / 
nitrosative stress marker and indirect measure of eNOS uncoupling) remained at 
control levels. (2) Investigations into the effects of OA on CMECs showed that 30 µM 
OA increased NO production after 5 and 20 min of incubation whereas 40 µM 
increased NO production after 20 min only. Pre-treatment with 40 µM OA 
significantly reversed ED by restoring NO production back to control levels. Data 
from cellular mechanism investigations showed that 40 µM OA significantly 
increased eNOS activation in both normal and dysfunctional CMECs. Cellular 
viability was not negatively affected by any of the above interventions.  
 
Discussion and Conclusions: Based on our findings, reduced activation of the 
PKB / Akt-eNOS pathway appears to be the primary mechanistic pathway of the 
TNF-α-induced model of ED. Though O2
- levels remained at control levels, the 
significant increase in p22-phox is indicative of increased expression of the O2
- 
producing enzyme, NADPH oxidase, thus suggesting oxidative stress. However, 
based on our nitrotyrosine expression data, there was no strong evidence of eNOS 
uncoupling in our ED model. OA significantly stimulated NO production in our model 
of CMECs. Furthermore, our findings showed that OA is able to reverse ED. The NO 
production stimulatory effects of OA in our cells appear to be achieved via the 
increased activation of eNOS.  
We have, for the first time as far as we are aware, developed a TNF-α-induced 
model of ED in myocardial capillary-derived endothelial cells. It appears that reduced 
activation of the PKB/Akt-eNOS pathway is the primary mechanism leading to 
decreased NO production in this model. However, we did find some evidence of 
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elevated oxidative stress, which led us to believe that eNOS uncoupling cannot be 
excluded as a mechanism of ED in our model. In this study, we report for the first 
time convincing evidence that OA has powerful NO-increasing properties in 
myocardial capillary-derived CMECs. Our study also show novel data, which suggest 
that OA is able to reverse ED in this model. Follow-up investigations could shed 
more light on the exact mechanisms underlying OA‟s effects in this model. 
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Abstrak 
 
Inleiding: Die ontdekking dat endoteel „n reguleerder van vaskulêre tonus is, en die 
gevolglike ontdekking dat stikstofoksied (NO) die belangrikste endoteel-afgeleide 
verslappingsfaktor (EDRF) is, het verskeie moontlikhede in aangaande pogings om 
kardiovaskulêre siektes te voorkom en hanteer, ontsluit. Endoteel-disfunksie (ED), 
word gedefineer as verlaagde NO biobeskikbaarheid en dus „n ingekorte vermoë van 
die endoteel om vaskulêre homeostase te handhaaf. ED verteenwoordig die eerste, 
omkeerbare stap in die ontstaan van aterosklerotiese siekte en word dus beskou as 
„n sterk instrument waarmee isgemiese hartsiekte voorspel kan word. Studies oor 
ED en sy onderliggende meganismes, veral in miokardiale kapillêre-afgeleide 
endoteelselle (kardiale mikrovaskulêre endoteelselle, CMECs), word redelik 
afgeskeep in die literatuur, en hierdie studie het dit ten doel gehad om die gaping in 
die literatuur aan te spreek. Oleanoliese suur (OA) is „n bio-aktiewe triterpenoïede 
wat gevind word in blaar ekstrakte van inheemse medisinale plante soos bv. 
Syzigium cordatum (Waterbessie boom). OA het bewese vasodilatoriese, 
hipoglukemiese en hipolipidemiese eienskappe. OA se effekte op CMECs, en sy 
moontlike rol in die omkering van ED, is egter onbekend, en hierdie studie het dit ten 
doel gehad om sulke effekte te ondersoek. 
 
Doelwitte: Die doelwitte van hierdie studie was: (1) Die vestiging van „n in vitro 
model van ED in gekultuurde CMECs afkomstig van miokardiale kapillêre deur 
protokolle vir die induksie van ED te ontwikkel. (2) Die evaluering van ED induksie 
deur die volgende bio-merkers te meet: (i) intrasellulêre NO produksie, (ii) 
superoksied (O2
-) produksie, (iii) nitrotirosien uitdrukking en (iv) NADPH oksidase 
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uitdrukking. (3) Die ondersoek na onderliggende sellulêre meganismes van ED in 
ons model deur die meting en vergelyking van eNOS and PKB/Akt uitdrukking en 
aktivering in kontrole en disfunksionele CMECs. (4) Ondersoek na die effekte van 
OA afkomstig van blaar ekstrakte verkry van Syzigium cordatum (Hochst.) 
[Myrtaceace], in beide kontrole en disfunksionele CMECs.  
 
Metodes: (1) Daar was gepoog om ED te induseer deur hiperglukemie en 
inflammasie te simuleer met onderskeidelik 25 mM glukose (24 uur) en 1 ng/ml TNF-
α (24 uur) of 5 ng/ml (6 en 24 uur) inkubasie. Verlaagde intrasellulêre NO produksie 
was ingespan as die hoof indikator van ED. NO produksie en sellewensvatbaarheid 
was gekwantifiseer deur vloeisitometriese analises (FACS) van die fluoresserende 
agense, DAF-2/DA en propidium jodied (PI) / Annexin V onderskeidelik. Sellulêre 
meganismes was ondersoek deur O2
- vlakke via FACS analise van DHE 
fluoressensie te meet, asook die meting van totale en geaktiveerde PKB / Akt en 
eNOS, p22-phox, nitrotirosien uitdrukking via Western blot tegnieke. (2) Effekte van 
OA op CMECs was ondersoek deur vooraf-behandeling met 30 of 40 µM OA vir 5 en 
20 min gevolg deur NO produksie en sellewensvatbaarheid metings.  
Resultate: (1) 25 mM glukose (24 uur), 1 ng/ml TNF-α (24 uur) and 5 ng/ml TNF-α 
(6 uur) kon nie daarin slaag om ED te induseer nie, soos blyk uit die verhoogde NO 
produksie waargeneem in die behandelde selle. „n Model van ED was suksesvol 
verkry deur CMECs met 5 ng/ml TNF-α (24 uur) te inkubeer, soos waargeneem deur 
verlaagde NO produksie. Ondersoek na sellulêre meganismes onderliggend tot ons 
TNF-α-geïnduseerde ED model, het getoon dat geaktiveerde eNOS en PKB / Akt 
vlakke verlaag was. Verder is gevind dat O2
- vlakke onveranderd gebly het hoewel 
p22-phox (NADPH) uitdrukking betekenisvol toegeneem het, wat ‟n aanduiding van 
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oksidatiewe skade is. Nitrotirosien vlakke („n oksidatiewe / nitrosatiewe stres merker 
en indirekte maatstaf van eNOS ontkoppeling) het onveranderd rondom kontrole 
vlakke gebly. (2) Ondersoek na die effekte van OA op CMECs het getoon dat 30 µM 
OA tot verhoogde NO produksie na 5 en 20 min inkubasie gelei het, terwyl 40 µM 
slegs na 20 min NO-verhogende effekte gehad het. Vooraf behandeling met 40 µM 
OA het ED betekenisvol omgekeer deur NO terug na kontrole vlakke te laat herstel. 
Ondersoek na sellulêre meganismes het getoon dat 40 µM OA eNOS aktivering 
betekenisvol verhoog het in beide normale en disfunksionele CMECs. Sellulêre 
lewensvatbaarheid was nie negatief geaffekteer deur enige van bogeneemde 
ingrepe nie.   
 
Bespreking en afleidings: Gebaseer op ons bevindinge, blyk verlaagde aktivering 
van die PKB/Akt-eNOS pad die primêre meganistiese pad in ons TNF-α-
geïnduseerde model van ED te wees. Alhoewel O2
- vlakke rondom kontrole vlakke 
gebly het, was die betekenisvolle toename in p22-phox „n aanduiding van verhoogde 
uitdrukking van die O2
- produserende ensiem, NADPH oksidase, wat dus 
suggererend van oksidatiewe stres was. Aan die ander kant was daar nie sterk 
bewyse van eNOS ontkoppeling in ons ED model nie, gebaseer op die nitrotirosien 
uitdrukking data. OA het duidelik NO produksie in ons model van CMECs 
gestimuleer. Verder wys ons resultate dat OA in staat is om ED om te keer. Die NO 
produksie-stimulerende effekte van OA in ons selle blyk die gevolg te wees van 
verhoogde aktivering van die PKB / Akt-eNOS pad.  
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Ons het hier vir die eerste keer, sover ons bewus is, „n TNF-α-geïnduseerde model 
van ED in CMECs afkomstig van miokardiale kapillêre gevestig. Dit blyk dat 
verlaagde aktivering van die PKB/Akt-eNOS pad die primêre meganisme was 
waardeur verlaagde NO produksie in ons model veroorsaak was. Ons het egter wel 
bewyse van verhoogde oksidatiewe stress gevind, wat ons laat glo dat eNOS 
ontkoppeling nie heeltemal as „n meganisme van ED in ons model uitgesluit kan 
word nie. In hierdie studie toon ons vir die eerste maal oortuigende bewyse dat OA 
kragtige NO-verhogende eienskappe in miokardiale kapillêre-afgeleide CMECs het. 
Ons studie bring ook nuwe data na vore, wat suggereer dat OA in staat is om ED in 
hierdie model om te keer. Opvolgstudies sal meer lig kan werp op die onderliggende 
meganismes van OA in hierdie model. 
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SOD superoxide dismutase 
Thr 495 Threonine 495 
TNF-α tumour necrosis factor-alpha 
TXA2 thromboxane A2 
VCAM vascular cell adhesion molecule 
VEGF vascular endothelial growth factor 
VSMCs vascular smooth muscle cells 
vWF von Willebrand factor 
WHO World Health Organisation 
WPBs Weibel-Palade bodies 
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Introduction 
 
In 2004, the World Health Organisation (WHO) reported cardiovascular diseases / 
ischaemic heart disease (IHD) to be the leading cause of death worldwide and that 
cardiovascular deaths are envisaged to escalate to 23.4 million by the year 2030 
(WHO 2009: http://www.who.int/healthinfo/global_burden_disease). In the year 2000, 
the Medical Research Council ranked IHD the number five cause of death in South 
Africa and the number one cause of death in the Western Cape Province under the 
non-communicable disease category (http://www.mrc.ac.za/bod/estimates.htm). 
Myocardial ischaemia is defined as reduced blood flow to the heart tissue, thus 
leading to oxygen and nutrient deprivation of the heart muscle and ultimately 
myocardial infarction (Choi et al 2009). Hypertension, tobacco use, hyperglycaemia, 
physical inactivity and obesity, all of which can potentially lead to atherosclerosis and 
eventually IHD, are considered to be the top risk factors for mortality worldwide 
(WHO 2009).  
 
Endothelial dysfunction (ED), characterised by reduced nitric oxide (NO) 
bioavailability and hence diminished vasorelaxation in larger, muscular blood 
vessels, is considered to be the key step in initiation of atherosclerosis and is a 
reliable predictor of cardiovascular disease (Bonetti et al 2003). Atherosclerosis is a 
progressive disease commonly described as the narrowing and hardening of arteries 
due to build up of fatty streaks in the arterial wall, and underlies the pathogenesis of 
IHD (Szmitko et al 2003). Owing to its reversibility, ED represents a potentially key 
therapeutic target in the prevention of atherosclerosis and hence IHD. This study 
aims to explore cellular mechanisms involved in the pathogenesis of ED in 
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myocardial capillary-derived endothelial cells, and investigate possible ED reversing 
effects of an African medicinal plant extract-derived bioactive compound. 
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Chapter 1: Literature review 
 
1.1 The endothelium 
Wilhelm His devised the term endothelium in 1865, describing a cell layer that lined 
the vascular system, lymphatic system and mesothelial-lined cavities such as pleura, 
peritoneum and pericardium (Aird 2007). As research advanced the term was later 
confined to the cell layer lining the vascular and lymphatic systems (Aird 2007). 
Many years after its discovery, the endothelium was perceived as nothing more than 
a passive semi-permeable barrier between blood and underlying tissues (Mas 2009). 
Its role as a highly metabolically active organ, maintaining vascular homeostasis and 
blood flow, has only become apparent in recent years (Esper et al 2006).  
 
In the larger, smooth muscle containing blood vessels, the endothelium is able to 
sense chemical or mechanical stimuli and elicit a response by producing a variety of 
vasoactive substances that can either dilate or constrict the blood vessel, depending 
on the type of the stimulus (Chhabra 2009). Under physiological conditions, the 
endothelium strives to maintain a balance between a vasoconstrictive state which is 
usually associated with pro-oxidant, pro-inflammatory and pro-thrombotic effects and 
a vasodilatory state which is usually associated with anti-oxidant, anti-inflammatory 
and anti-thrombotic effects [fig. 1.1] (Strijdom & Lochner 2009). A vasodilatory state 
is mediated by factors such as nitric oxide (NO), endothelium derived hyperpolarising 
factor (EDHF) and prostacyclins, while a vasoconstrictive state is mediated by 
factors such as endothelin-1 (ET-1), angiotensin II and thromboxane A2 (Strijdom & 
Lochner 2009; Chhabra 2009).     
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Figure 1.1: The endothelium maintains vascular homeostasis by regulating the intricate balance 
between a vasodilatory, anti-thrombotic, anti-inflammatory and an anti-oxidant state mediated by NO, 
prostacyclin and EDHF; and a vasoconstrictory, pro-thrombotic, pro-inflammatory and pro-oxidant 
state mediated by factors such as endothelin-1, angiotensin II and thromboxane. (Modified from 
Strijdom & Lochner 2009) 
 
 
1.1.1 Anatomy and structure of the endothelium  
The adult human endothelium is estimated to have a surface area of between 1 to 
7000 m2 (Limaye & Vadas 2006; Mas 2009), consisting of 1-6 × 1013 endothelial cells 
and  approximated to account for about 1 kg of total body weight (Sumpio et al 2002; 
Limaye & Vadas 2006). An endothelial cell is flat with a large central nucleus, having 
a diameter of no more than 0.5 μm (Mas 2009) and shows distinct phenotypic 
characteristics from site to site in the vascular tree. They exhibit a circular shape in 
capillaries and venules whereas they are spindle shaped and arranged in the same 
direction as blood flow in arteries and arterioles (Mas 2009; Aird 2007). The plasma 
membranes of endothelial cells are profusely supplied with caveolae (Xu et al 2008). 
Caveolae are small lipid enriched invaginations of the plasma membrane which can 
be characterised by the presence of the protein caveolin (Dudzinski & Michel 2007). 
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Caveolae are generally thought to play a role in endocytosis, transcytosis and signal 
transduction (Xu et al 2008). They also control NO production through binding of 
endothelial nitric oxide synthase (eNOS; the most important enzyme responsible for 
NO production in endothelial cells) via protein caveolin, specifically caveolin-1 (Xu et 
al 2008). 
 
Similar to most metabolically active cells, endothelial cells contain substantial 
numbers of mitochondria (Mas 2009). However, these cells preferentially derive their 
energy (ATP) anaerobically rather than from mitochondrial oxidative phosphorylation 
(Davidson & Duchen 2007). This led to a proposal that the principal role of 
mitochondria in endothelial cells may be to release nitric oxide (NO) and reactive 
oxygen species (ROS) as signalling molecules (Quintero et al 2006). Rod-shaped 
structures called Weibel-Palade bodies (WPBs) are uniquely expressed by 
endothelial cells (Weibel & Palade 1964) and are the major stores of the 
procoagulant von Willebrand factor (vWF) and some proinflammatory proteins 
including P-selectin (Mas  2009). Fusion of the WPBs with the cell membrane, 
followed by emptying of their contents into the blood is considered the first reaction 
to endothelial cell or vascular insult (Mas  2009).  
 
 
Over the years, it has become apparent that the endothelium shows some structural 
heterogeneity across the vascular tree (Aird 2007). For example, tight junctions 
between endothelial cells of the larger arteries are better developed, which might 
reflect a structural adaptation to shear stress. In the microcirculation, the arterioles 
have tighter junctions than do capillaries whereas tight junctions at venules are loose 
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(Aird 2007). Not only do various endothelial cell subtypes differ structurally, but they 
have also been reported to show differences in antigenic properties and in their 
response to growth factors across the vascular tree (Ando et al 1999). 
 
1.1.2 Endothelial cells in the heart 
The endothelium has indeed emerged as an autocrine and paracrine signalling 
organ that has a far more complex and crucial role in maintaining cardiovascular 
health than merely serving as a barrier (Hsieh et al 2006). In the heart, endothelial 
cells can be categorised based on their proximity and interaction with the 
cardiomyocytes [fig. 1.2] (Strijdom & Lochner 2009). Endocardial endothelial cells, 
(EECs; endocardial endothelium) line the inner surface of the heart chamber walls, 
acting as barrier between circulating blood and the myocardium (Andries et al 1996). 
Owing to their close proximity with adjacent cardiomyocytes, EECs, together with the 
cardiac microvascular endothelial cells (CMECs; cells that line the myocardial 
capillaries), constitute the cardiac endothelium [Fig. 1.2] (Brutsaert 2003).  
 
The cardiac endothelium has direct effects on the functioning and activity of 
cardiomyocytes. These effects include regulating metabolism, growth, contractility 
and rhythmicity and are mediated by autocrine and paracrine secretion of 
substances such as NO, ET-1, prostacyclins and a variety of growth factors 
(Brutsaert 2003; Hsieh et al 2006). On the other hand, endothelial cells from larger 
coronary arteries, which constitute the coronary vascular endothelium [Fig. 1.2], lie 
distant from cardiomyoctes (Strijdom & Lochner 2009) and indirectly affect the 
functioning and activity of cardiomyocytes by modulating blood supply to the 
myocardium (Brutsaert 2003). 
29 
 
 
 
Figure 1.2: Classification of the endothelium in the heart. The coronary vascular endothelium is 
comprised of epicardial coronary artey and vein endothelial cells, and intramyocardial artery and vein 
endothelial cells and primarily target VSMCs. The cardiac endothelium is made up of EECs and 
CMECs which primarily targets cardiomyocytes. (Modified from Strijdom and Lochner 2009) 
 
 
Owing to their location, EECs are exposed to 100 % of circulating blood unlike 
CMECs, which only receive about 3-5 % of the circulation (Brutsaert et al 1998). 
From this, Brutsaert et al (1998) deduced that aside from regulating the function and 
activity of the myocardium, EECs may also act as sensor of total blood derived 
factors. Furthermore, EECs have abundant microvilli and therefore a large contact 
surface area, contributing to the notion of a sensory function (Kuruvilla & Kartha 
2003). The 3-5 % circulation that CMECs are exposed to would suggest that the 
concentration and partial pressure of blood derived factors, and not their total 
amount, would be of more importance in ensuring maximal diffusion between 
CMECs and cardiomyocytes (Brutsaert et al 1998). Since capillaries lack a vascular 
smooth muscle layer, the CMECs, unlike endothelial cells of the larger vessels do 
not exert vaso-active effects. Rather, it is likely that CMECs probably exclusively act 
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as regulators of myocardial function via autocrine and paracrine signalling (Brutsaert 
et al 1998). 
 
It has been reported that for each cardiomyocyte there are at least 3 cardiac 
endothelial cells. Cardiomyocytes are estimated to vary between 10-100 μm in 
diameter and the intercapillary distance is approximated to vary between 15-50 μm   
[fig. 1.3]. The distance between each CMEC and the closest cardiomyocyte is 
approximately 1μm. This strategic arrangement facilitates endothelial cell-to-
cardiomyocyte paracrine signalling (Brutsaert 2003).  
 
 
Figure 1.3: Myocardial capillary-to-cardiomyocyte distance. Each cardiomyocyte is about 10-100 µm 
in diameter and is surrounded by at least 3-4 myocardial capillaries. The intercapillary distance is 
about 10-50 µm. (Modified from Strijdom & Lochner 2009) 
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1.1.3 Endothelial cell-to-cardiomyocyte interaction 
In the larger conduit vessels, endothelial cells act in a paracrine manner to regulate 
contraction/relaxation of the underlying vascular smooth muscle cells (VSMCs) via 
release of endothelium-derived factors such as NO, prostacyclin, ET-1 and 
angiotensin II. Since cardiac endothelial cells are in close proximity to 
cardiomyocytes, and not VSMCs, it would therefore be expected that they act in a 
paracrine manner to primarily influence the contractile activity of the underlying 
cardiomyocytes. Indeed there is evidence suggesting that cardiac endothelial 
derived factors act in both an autocrine and paracrine fashion to regulate function of 
cardiomyocytes [fig. 1.4] (Brutsaert et al 1998; Brutsaert 2003; Hsieh et al 2006; 
Shah & MacCarthy 2000). 
 
 
Figure 1.4: CMEC-to-cardiomyocyte interaction. CMECs regulate cardiomyocyte growth, contractile 
function and rhythmicity via paracrine release of factors such as NO, ET-1, angiotensin-II and 
neuregulin. Cardiomyocytes can in turn release factors such as NO, angiopoietin-1 and vascular 
endothelial growth factor-A (VEGF-A) that affect function and activity of CMECs. (Modified from 
Strijdom & Lochner 2009) 
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1.2. Normal endothelial function and endothelium-derived factors 
1.2.1 Nitric oxide (NO) 
The discovery that the endothelium-derived relaxing factor (EDRF) was in fact NO 
was rather astonishing, as NO had up till then been perceived as nothing more than 
a toxic environmental pollutant (Strijdom et al 2009 (a)) found in cigarette smoke, 
exhaust fumes of motor cars and industrial processes (Bruckdorfer 2005). In addition 
to its vasodilatory properties, NO was also found to inhibit platelet aggregation and 
their adhesion to VSMCs (Moncada et al 1988). This breakthrough led to an 
understanding of the mechanisms by which nitrovasodilators such as nitroglycerin 
and amyl nitrite brought about relief from angina pectoris (Moncada et al 1988; 
Strijdom et al 2009 (a)). To date, a vast number of studies have indeed proven that 
this molecule is endogenously synthesised in the body and plays a vital role in 
maintaining a healthy cardiovascular system (Strijdom et al 2009 (a)).  
 
NO is a free radical gas with a half life of about 3-5 seconds (Rodeberg et al 1995).   
Owing to its gaseous and free radical nature, NO is able to diffuse easily between 
cells and tissues and react with a variety of molecules in the body (Strijdom et al 
2009 (a)). Following its identification as the EDRF, it was reported that NO is 
synthesised from the amino acid L-arginine by a family of enzymes known as nitric 
oxide synthase (NOS) (Bruckdorfer 2005). 
 
1.2.1.1 Nitric oxide synthase (NOS)  
NOS enzyme occurs in three isoforms, namely neuronal NOS (nNOS), inducible 
NOS (iNOS) and endothelial NOS (eNOS) (Bruckdorfer 2005; Balligand & Cannon 
1997; Bryan et al 2009). These isoforms were named according to where they were 
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first isolated. However, through advancement of research, it is now appreciated that 
cells can express more than one of these isoforms and that they are not exclusive to 
the area where they were first isolated (Bruckdorfer 2005; Bryan et al 2009). For 
example it has been found that the heart expresses all three isoforms (Balligand & 
Cannon 1997).  iNOS was first discovered in macrophages  and its expression as 
the name suggest, is induced by external stimuli such as cytokines (Balligand & 
Cannon 1997). Since these isoforms are not necessarily confined to the areas where 
they were initially isolated, they have also been named according to their order of 
isolation and cloning. nNOS, being the first isoform to be isolated, is also known as 
NOS I, iNOS (NOS II) was the second to be discovered and  eNOS (NOS III) was 
the third to be isolated (Bruckdorfer 2005; Bryan et al 2009).   
 
Physiologically, eNOS and nNOS are constitutive, calcium dependent enzymes and 
continuously produce low levels of NO. On the other hand, iNOS is calcium 
independent, its expression provoked by inflammatory cytokines, and producing 
large amounts of NO, about 1000-fold more than eNOS or nNOS (Strijdom et al 
2009 (a)). This is potentially harmful as excess NO can react with the free radical 
superoxide anion (O2
-) yielding another very harmful free radical known as 
peroxynitrite (Strijdom et al 2009 (a)). All NOS isoforms function optimally as 
homodimers (Balligand & Cannon1997; Bryan et al 2009) and require cofactors such 
as (6R)-5,6,7,8-tetrahydobiopterin (BH4), flavin adenine dinucleotide (FAD), flavin 
mononucleotide (FMN), and iron protoporphyrin IX (haem) (Alderton et al 2001). Of 
the three isoforms, it has been proposed that eNOS is the major isoform responsible 
for NO production under physiological conditions in the cardiovascular system and 
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endothelial cells in particular (Dudzinski & Michel 2007) and thus, for the purpose of 
this study, eNOS will be the isoform of interest. 
 
1.2.1.2 eNOS and biosynthesis of NO 
eNOS, as all other NOS isoforms, is synthesised as two separate monomers which 
must form a dimer in order to catalyse formation of NO [fig. 1.5] (Forstermann & 
Munzel 2006). Each monomer contains a C-terminal reductase domain which binds 
cofactors such as nicotinamide adenine dinucleotide phosphate (NADPH), FAD, 
FMN and haem, and an N-terminal oxygenase domain that binds the cofactors BH4 
and oxygen and the substrate L-arginine (Forstermann & Munzel 2006; Alderton et al 
2001). These cofactors, in particular BH4, haem and L-arginine support and stabilise 
the dimeric structure of eNOS (Forstermann & Munzel 2006; Alderton et al 2001), in 
fact, haem is required for the dimerisation (Forstermann & Munzel 2006). At the 
interface of the dimer, a zinc ion is found tetrahedrally arranged to two cysteine 
residues from each monomer forming a zinc thiolate cluster. This site is crucial for 
the binding of BH4 and L-arginine (Forstermann & Munzel 2006; Alderton et al 
2001).  
 
During synthesis of NO, electrons flow from NADPH in the reductase domain via the 
flavins to the haem in the oxygenase domain (Steuhr et al 2001). Calmodulin, which 
is very important for eNOS activation, accelerates the rate of electron transfer across 
the reductase domain to the haem. Upon reaching the haem, these electrons reduce 
and activate oxygen (Steuhr et al 2001). eNOS catalyses conversion of L-arginine 
into NO in two steps. First L-arginine is hydroxylated to N-hydroxyl-L-arginine which 
is finally oxidised to NO and L-citrulline as a by-product (Steuhr et al 2001). Failure 
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of the enzyme to dimerise or absence of any of the cofactors mentioned above leads 
to the enzyme catalysing formation of O2
- instead of NO, a mechanism referred to as 
eNOS uncoupling (Forstermann & Munzel 2006). A disruption in the flow of electrons 
can also lead to eNOS uncoupling (Forstermann & Munzel 2006). 
 
Figure 1.5: Structure and function of eNOS. A. eNOS is synthesised as monomers which must 
dimerize to catalyse production of NO. B. The two monomers come together and form a homodimer 
in the presence of the haem. However, without all the necessary cofactors and the substrate, eNOS 
catalyses formation of superoxide instead of NO. C. In the presence of all cofactors and the substrate 
L-arginine, eNOS can successfully catalyse conversion of L-arginine into NO and the by-product, L-
citrulline. (Copied from Fostermann & Munzel 2006)  
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1.2.1.3 eNOS activation and phosphorylation 
Activity of eNOS is regulated by intricate mechanisms such as subcellular 
localisation to caveolae, post-translational alterations such as phosphorylation, and 
association with regulatory proteins such as heat shock protein 90 (Hsp90) [fig. 1.6] 
(Takahashi & Mendelsohn 2003 (a)). Membrane-bound eNOS is localised to 
caveolae, where it interacts with the caveolae bound protein, caveolin-1 (Dudzinski & 
Michel 2007; Govers & Rabelink 2001). This interaction keeps eNOS inactive by 
attenuating binding of calmodulin to eNOS at low levels of calcium and thus 
hindering production of NO (Govers & Rabelink 2001). A surge in intracellular 
calcium mainly due to stimuli such as acetylcholine or bradykinin, prompts 
calmodulin to bind to eNOS resulting in displacement of eNOS from caveolin and 
activation of the enzyme (Bryan et al 2009, Dudzinski & Michel 2007, Govers and 
Rabelink 2001). This mechanism serves to regulate NO production under 
physiological conditions (Takahashi & Mendelsohn 2003 (b)). 
 
Phosphorylation of eNOS by  protein kinase B / Akt (PKB/Akt) at the serine 1177 
(Ser 1177) site and interaction with Hsp90 are examples of complementary 
activation mechanisms of eNOS in addition to baseline, constitutive calcium-
calmodulin activation (Dudzinski & Michel 2007). PKB/Akt is a serine/threonine 
kinase which activates eNOS by phosphorylating its Ser 1177 residue usually in 
response to stimuli such as shear stress, vascular endothelial growth factor (VEGF),  
insulin (Govers and Rabelink 2001) and hypoxia (Strijdom et al 2009 (b)). PKB/Akt 
stimulates activity of eNOS by either accelerating rate of electron transfer or 
diminishing dissociation of calmodulin from eNOS and may act independently of 
calcium (McCabe et al 2000; Dimmeler et al 1999). For example, Dimmeler et al 
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(1999) showed that PKB/Akt mediated eNOS phosphorylation in response to shear 
stress remained unaltered following the removal of calcium or antagonising of 
calmodulin by calmidazolium.  
 
Other protein kinases such as protein kinase A (PKA), protein kinase C (PKC), AMP-
activated protein kinase (AMPK), protein kinase G (PKG) and calcium/calmodulin-
dependent protein kinase II (CaM kinase II) may also be involved in eNOS 
phosphorylation and depending on the phosphorylation site, may have a stimulatory 
or an inhibitory effect (Dudzinski & Michel 2007). Phosphorylation at threonine 495 
(Thr 495) and Ser 116 inactivates eNOS, while phosphorylation sites such as        
Ser 635 and 617 in addition to the better characterised Ser 1177 site have an 
activating effect on eNOS (Li C et al 2007; Bauer et al 2003). Both PKA and PKB/Akt 
may mediate phosphorylation at Ser 617 leading to enhancement of binding of 
calmodulin to eNOS and thus eNOS activation (Michell et al 2002). Residue Ser 635 
is phosphorylated by PKA while the inhibitory Thr 495 site is phosphorylated by PKC 
and AMPK, thereby inactivating eNOS by weakening eNOS-calmodulin interaction 
(Mount et al 2007, Dudzinski & Michel 2007). PKA, AMPK, PKG, and CaM kinase II 
can also phosphorylate eNOS at the Ser 1177 site (Dudzinski & Michel 2007; Mount 
et al 2007).  
 
Hsp90, a molecular chaperone that participates in protein trafficking and folding, has 
also been implicated in eNOS activation (Michel & Vanhoutte 2010; Dudzinski & 
Michel 2007). Agonists such as VEGF, histamine, oestrogen, and shear stress 
induce binding of Hsp90 to eNOS (Takahashi & Mendelsohn 2003 (b)). Hsp90 
increases eNOS activity by enhancing the binding of calmodulin to eNOS without a 
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rise in calcium or by stimulating flow of electrons in the reductase domain and thus 
augmenting eNOS activity (Takahashi & Mendelsohn 2003 (b)). According to 
Takahashi and Mendelsohn (2003) (a), PKB/Akt and Hsp90 can act synergistically to 
increase activity of eNOS.  
 
 
Figure 1.6: Regulation of eNOS activity. Inactive eNOS is targeted to the plasma membrane caveolae 
by interaction with caveolin-1. Upon stimulation or presence of an eNOS agonist such as shear stress 
and bradykinin, a rise in intracellular calcium, phosphorylation of eNOS, or binding of Hsp90, binding 
of eNOS to calmodulin (CaM) is enhanced. Binding of CaM disrupts the inhibitory interaction between 
eNOS and caveolin-1 leaving eNOS catalytically active to produce NO. (Copied from Bredt 2003) 
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1.2.1.4 Downstream mechanisms of NO 
NO elicits its biological effects by binding to a haem-containing cytosolic enzyme, 
soluble guanylyl cyclase (sGC) [Fig. 1.7] (Bruckdorfer 2005). sGC is a heterodimeric 
enzyme composed of two subunits namely α and β. Each of these subunits occurs in 
two isoforms; α1, α2 and β1, β2 and the heterodimers are arranged as α1/β1 or α2/β1 
respectively (Bruckdorfer 2005; Bryan et al 2009). The α1/β1 is the most predominant 
heterodimeric form of sGC and is widely expressed in tissues such as the heart, 
brain, lung, kidney, spleen and muscle (Bruckdorfer 2005; Bryan et al 2009). Binding 
of NO to the haem moiety of this heterodimeric enzyme activates it to catalyse 
conversion of guanosine triphosphate (GTP) into the second messenger guanosine 
3‟:5‟-cyclic monophosphate (cGMP) (Bruckdorfer 2005; Bryan et al 2009; Gewaltig & 
Kojda 2002). cGMP then in turn activates two cGMP-dependent protein kinases 
(PKG I and PKG II) (Gewaltig & Kojda 2002). Of these two kinases, PKG I is crucial 
for vasodilation and platelet aggregation inhibition. Activation of PKG I results in 
subsequent phosphorylation of a variety of membrane proteins, which in turn 
mediates the reduction of intracellular calcium levels and thus relaxation of the 
VSMCs [fig. 1.7]. Inhibition of platelet aggregation is also mediated via reduction of 
intra-platelet calcium concentration (Gewaltig & Kojda 2002). 
 
The activity of cGMP is abolished by a family of hydrolytic enzymes called 
phosphodiesterases (PDE), particularly PDE 5, which hydrolyses cGMP into its 
inactive form GMP (Bryan et al 2009; Gewaltig & Kojda 2002). 
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Figure 1.7: Downstream mechanisms of NO. After synthesis of NO in the endothelial cells, NO 
diffuses into the underlying VSMCs where it activates the sGC-cGMP-PKG pathway, which results in 
inhibition of the L-type calcium channels and the reduction of intracellular calcium levels. (Copied from 
Strijdom et al 2009 (a)) 
 
 
1.2.1.5 Physiological roles of NO 
Subsequent relaxation of the underlying vascular smooth muscle after NO 
production is the most well-known biological effect of NO in the vasculature 
(Gewaltig &Kojda 2002; Rastaldo et al 2007). However, the role that NO plays in 
maintaining vascular homeostasis extends beyond vasodilation in numerous ways 
including inhibition of detrimental factors such as smooth  muscle cell proliferation 
and migration, platelet adhesion to endothelial cells and platelet aggregation and low 
density lipoprotein (LDL) oxidation (Yetik-Anacak & Catravas 2006; Balligand & 
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Cannon 1997). NO is also known to inhibit expression of adhesion molecules and 
white blood cell adhesion to endothelial cells (Yetik-Anacak & Catravas 2006; 
Balligand & Cannon 1997). Augmentation of these factors due to a reduction in NO 
bioavailability (i.e. ED) has been implicated in pathophysiological conditions such as 
hypercholesterolemia, hypertension and diabetes which are all considered risk 
factors of cardiovascular diseases (Yetik-Anacak & Catravas 2006). 
 
1.2.1.6 NO in the heart 
Cardiomyocytes have been reported to express eNOS and are thus capable of 
generating NO (Balligand & Cannon 1997). However, comparative studies have 
demonstrated that the cardiac endothelium expresses higher levels of eNOS than do 
cardiomyocytes and thus produce more NO (Shah & MacCarthy 2000; Brutsaert 
2003; Hsieh et al 2006). This was recently confirmed by Strijdom et al (2006) via 
direct measurement of intracellular NO production in both cardiomyocytes and 
CMECs using a fluorescence-based technique. Their model of CMECs generated 26 
times more NO per cell and exhibited a higher eNOS expression than 
cardiomyocytes, further highlighting the potential role of CMECs as putative 
paracrine regulators of cardiomyocytes. In the heart, the effects of NO involve more 
than regulation of vascular homeostasis. NO has been shown to play a role in 
regulation of contractile performance, heart rate, cardiac metabolism and modulation 
of cardiac growth (Brutsaert 2003), and the cardioprotective response of the heart to 
ischaemia-reperfusion injury (Bolli 2001). 
 
Regulation of myocardial contractility is mediated by the NO-sGC-cGMP pathway. At 
low levels of NO, cGMP inactivates PDE 3, a phosphodiesterase which hydrolyses 
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3‟:5‟-cyclic adenosine monophosphate (cAMP) to its inactive form AMP. NO can also 
act independently of cGMP by directly activating the β-adrenergic-adenylyl cyclase 
(AC) which catalyzes hydrolysis of ATP to cAMP (Rastaldo et al 2007; Ziolo et al 
2008). Consequently cAMP accumulates in the cardiomyocytes and activates PKA 
which in turn mediates the opening of the voltage-gated calcium channels and 
subsequent intracellular influx of calcium resulting in a positive inotropic effect 
(myocardial contraction). Conversely, at high concentrations of NO, the cGMP-PKG 
pathway is activated resulting in a negative inotropic effect (myocardial relaxation) 
(Rastaldo et al 2007; Schulz et al 2004). 
 
The growth-modulating role of NO on cardiomyocytes includes promoting growth and 
survival during cardiac development and suppressing growth in the adult heart in 
attempt to prevent cardiac remodelling (Brutsaert 2003). Mice lacking eNOS were 
shown to have a high incidence of cardiomyocyte apoptosis (Brutsaert 2003). 
Bradykinin (an eNOS agonist) has been reported to promote growth of 
cardiomyocytes in culture. However when adult cardiomyocytes are co-cultured with 
endothelial cells, bradykinin suppresses cardiomyocyte growth instead (Brutsaert 
2003). Therefore the growth suppression effect in adult cells appears to be 
dependent on endothelium-derived NO and PGI2, further highlighting the importance 
of cardiac endothelial-cardiomyocyte interaction (Brutsaert 2003). In addition to 
regulating growth, NO regulates cardiac metabolism by modulating cardiac oxygen 
consumption both in normal and disease conditions (Brutsaert 2003). For example, 
non-selective inhibition of NOS has been reported to increase myocardial oxygen 
consumption in both physiological and disease setting, thus posing a risk of oxygen 
toxicity (Chen et al 2002).  
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NO has been shown to play a role in ischaemia-reperfusion (Bolli 2001). However, 
the role NO plays in ischaemia-reperfusion is contradictory with some studies 
reporting beneficial effects and others reporting harmful effects in non-
preconditioned hearts (Bolli 2001). The beneficial effects of NO include prevention of 
ischaemia-reperfusion injury (Flogel et al 1999). The harmful effects of NO during 
ischemia-reperfusion may be attributable to enhanced formation of reactive nitrogen 
species (RNS) e.g. peroxynitrite produced from the reaction of NO and O2
- (Flogel et 
al 1999). Nonetheless, according to Bolli (2001), most studies demonstrate that NO 
is protective during ischaemia-reperfusion injury. eNOS transgenic mice 
demonstrated decreased infarct size after ischaemia-reperfusion suggesting a role of 
eNOS derived NO in cardioprotection during ischaemia-reperfusion injury (Jones et 
al 2004). NO has been shown to play a role in both early and late ischaemic 
preconditioning (Jones & Bolli 2006). However, its effects are more pronounced 
during late ischaemic preconditioning. Cardioprotection during late ischaemic 
preconditioning comprises an initial activation of eNOS and delayed subsequent 
activation of iNOS suggesting a biphasic role of both eNOS and iNOS derived NO 
(Jones & Bolli 2006). Recent advances in research demonstrate postconditioning as 
another possible cardioprotective mechanism (Zhao et al 2003). Postconditioning 
has been reported to prompt PKB / Akt and eNOS activation and inhibition of the 
upstream activator of PKB / Akt, phoshatidyl-inositol-3-kinase (PI-3K), has been 
shown to abolish the cardio-protective mechanism of postconditioning, indicating NO 
as a key role player (Tsang et al 2004; Yang et al 2005).   
44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45 
 
1.2.2 Prostacyclin and Thromboxane A2 
Prostacyclin (PGI2) and thromboxane A2 (TXA2) are other endothelium-derived 
factors which play a role in maintenance of the vascular homeostasis (Fetalvero et al 
2007). The actions of these two factors appear to oppose each other, with PGI2 
having vasodilatory and anti-platelet aggregation properties, and TXA2 having 
vasoconstrictory and platelet activating properties (Fetalvero et al 2007). PGI2 and 
TXA2 are prostanoids which belong to a family of prostaglandins derived from the 
fatty acid arachidonic acid (Fetalvero et al 2007; Mas 2009). The enzyme, 
cyclooxygenase (COX), which occurs in two isoforms, COX-1 for synthesis of TXA2 
and COX-2 for synthesis of PGI2 [fig. 1.8], catalyses conversion of arachidonic acid 
to prostaglandin H2 (PGH2) which is further metabolised to TXA2 by thromboxane 
synthase and PGI2 by prostacyclin synthase respectively (Fetalvero et al 2007; Mas 
2009). Maintaining a synthetic balance between these two prostanoids is critical for 
cardiovascular health (Fetalvero et al 2007). This was demonstrated by selective 
inhibition of COX-2, which lowered PGI2 production without altering TXA2 production 
shifting the balance in favour of TXA2 leading to loss of vascular homeostasis and 
ultimately, initiation of vascular dysfunction (Fetalvero et al 2007). 
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Figure 1.8: Production of prostacyclin (PGI2) and thromboxane (TXA2). COX metabolises arachidonic 
into prostaglandin G2 (PGG2) and prostaglandin H2 (PGH2). PGH2 is finally metabolised into PGI2 by 
prostacyclin synthase in the endothelial cells (EC) or into TXA2 by thromboxane synthase in the 
platelets. PGI2 inhibits thrombosis whereas TXA2 promotes thrombosis. (Modified from Fetalvero et al 
2007) 
 
 
1.2.3 Endothelium-derived hyperpolarising factor (EDHF) 
EDHF is another known endothelium-derived vasodilator and causes relaxation of 
the VSMCs by means of membrane hyperpolarisation (Mas 2009) particularly in 
small arteries with a diameter of ≤ 300 µm (Luksha et al 2009). Its effects have been 
observed after pharmacological blocking of NO and PGI2 synthesis (Mas 2009) 
suggesting that EDHF may act as supporting vasodilatory mechanism when NO 
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production is reduced (Luksha et al 2009; Deanfield et al 2007). The identity of 
EDHF is very controversial and several diffusible substances have been suggested 
such as epoxyeicosatrienoic acid (derived from arachidonic acid by cytochrome 
P450), potassium ions, hydrogen peroxide (H2O2), C type-natriuretic peptide and 
endocannabinoids (Mas 2009; Luksha et al 2009).  
 
1.2.4 Endothelin-1 (ET-1)  
ET-1 is one of the most potent vasoconstrictors released by endothelial cells due to 
stimuli such as hypoxia, angiotensin II (another potent vasoconstrictor), thrombin, 
platelet products, inflammatory cytokines, noradrenaline and vascular wall tension 
(Mas 2009). ET-1 elicits its effects via two receptors, namely ETA and ETB. Of these 
receptors, ETB receptors are predominantly expressed in endothelial cells and ETA 
on VSMCs. Activation of ETA enhances vascular contraction whereas activation of 
ETB stimulates eNOS activity leading to NO production and ultimately reduction in 
ET-1 production.  ETB receptor thus antagonises the vasoconstrictive action of ET-1 
(Mas 2009). 
 
In the heart, ET-1 has been reported to exert autocrine effects by binding to ETB 
receptors on cardiac endothelial cells resulting in release of NO and prostacyclin and 
ultimately vasodilation (Hsieh et al 2006). Its paracrine effects are achieved by 
binding to ETA receptors expressed on underlying cardiomyocytes leading to 
myocardial contraction (Hsieh et al 2006).  
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1.2.5 Angiotensin ll  
Another potent vasoconstrictor released by endothelial cells is known as    
angiotensin II. Formation of angiotensin II results from conversion of angiotensin I to 
angiotensin II by the enzyme angiotensin converting enzyme (ACE), which is 
expressed in the cardiovascular system and is also found in the circulation (Dostal & 
Baker 1999; Mas 2009). ACE is expressed in CMECs and cardiomyocytes, 
suggesting the production of angiotensin II in both these cell types (Brutsaert 2003). 
Angiotensin II acts in an autocrine and paracrine manner to influence growth of 
cardiomyocytes (Brutsaert 2003). 
 
Angiotensin II elicits its effects via two receptors, AT1 and AT2 (Dostal & Baker 1999; 
Schmieder et al 2007). Activation of AT1 receptor is associated with effects such as 
vasoconstriction and cell proliferation whereas AT2 receptors appear to oppose such 
effects (Schmieder et al 2007). Augmented binding of angiotensin II to AT1 receptors 
has been associated with production of pro-inflammatory cytokines, enhanced 
activity of NADPH and xanthine oxidase leading to generation of oxygen free 
radicals, oxidation of LDL and hence ED (Schmieder et al 2007). 
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1.3 Endothelial dysfunction (ED) 
 ED is commonly described as reduced NO bioavailability or an inability of the 
endothelium to initiate vasodilation in response to stimuli such acetylcholine or shear 
stress and is considered a predictor of atherosclerosis and hence ischaemic heart 
disease (Chhabra 2009; Bonetti et al 2003). ED comprises a loss of balance 
between endothelial-derived vasodilatory and vasoconstrictive factors, where 
vasoconstrictive factors and effects become dominant leading to a 
pathophysiological state termed endothelial activation i.e. a pro-inflammatory, pro-
oxidant, proliferative, pro-coagulatory and pro-adhesive state (Chhabra 2009; Bonetti 
et al 2003). Chronic exposure to cardiovascular risk factors such as hyperglycaemia, 
hyperlipidaemia, hypertension, tobacco smoking, etc., overwhelms the defensive 
mechanisms of the endothelium compromising the integrity of the endothelium and 
ultimately initiating ED (Deanfield et al 2007).  
 
 
1.3.1 Cardiovascular risk factors associated with ED 
1.3.1.1 Diabetes/ insulin resistance 
Both type 1- and type 2 diabetes are independent risk factors of cardiovascular 
disease (Esper et al 2006). The endothelial damage or dysfunction that is observed 
in diabetic conditions may be attributable to upregulated expression and activity of 
NADPH oxidase, and increased formation of advanced glycation end-products 
(AGEs) (Guzik et al 2002; Avogaro et al 2008).  NADPH oxidase is the main source 
of reactive oxygen species (ROS) in the vascular system, and thus its increased 
activity is associated with increased O2
- production (Guzik et al 2002; Avogaro et al 
2008). However, other enzymatic sources of ROS such as xanthine oxidase, COX 
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and uncoupled eNOS may also play a role (Guzik et al 2002). Not only does O2
- 
scavenge NO leading to production of the potent oxidant peroxynitrite, but it also 
modifies activity and regulation of eNOS, and promotes VSMC proliferation and 
inflammation (Guzik et al 2002). 
 
Excess blood sugar results in non-enzymatic glycation of intracellular and 
extracellular proteins and lipids forming AGEs, which accumulate in the vascular wall 
and reduce NO activity by quenching NO (Avogaro et al 2008; Soldatos et al 2005). 
The AGEs bind to specific surface receptors called receptor for AGE (RAGE) which 
are expressed on cells such as monocytes, macrophages and VSMCs resulting in 
amplification of an inflammatory response (Avogaro et al 2008; Soldatos et al 2005). 
Binding of AGEs to these receptors also results in increased vascular permeability, 
expression of vascular cell adhesion molecule (VCAM) and intercellular adhesion 
molecule (ICAM), and oxidative stress (Soldatos et al 2005). 
 
Furthermore, hyperglycaemia activates PKC which decreases eNOS activity leading 
to reduced NO and increased ET-1 production (Avogaro et al 2008). In the setting of 
ED, ETB receptor-mediated effects of ET-1 are blunted and thus the vasoconstrictory 
effects predominate (Versari et al 2009). PKC also enhances expression of adhesion 
molecules such as ICAM, VCAM and E-selectin (Avogaro et al 2008). 
 
ED has been reported to occur early in insulin resistance (Hsueh et al 2004). Often 
insulin resistance is associated with central adiposity and hence the metabolic 
syndrome i.e. hypertriglyceridaemia, low high density lipoprotein (HDL) levels, high 
low density lipoprotein (LDL) levels and hypertension, all of which favour 
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development of ED and eventually atherogenesis (Hsueh et al 2004). It has therefore 
been suggested that advancement of insulin resistance to type 2 diabetes parallels 
advancement of ED to atherosclerosis [fig. 1.9] (Hsueh et al 2004). 
 
 
Figure 1.9: A parallel relationship is proposed to exist between progression of insulin resistance to   
type 2 diabetes and progression of endothelial dysfunction to atherosclerosis. (Modified from Hsueh 
et al 2004) 
 
 
1.3.1.2 Hyperlipidaemia 
Hyperlipidaemia constitutes increased circulating lipids including cholesterol and 
triglycerides, a state which predisposes to ED. Mechanisms underlying 
hyperlipidaemia-induced ED include upregulation of NADPH oxidase and thus 
oxidative stress, increased plasma levels of asymmetric dimethylarginine (ADMA) 
(Warnholtz et al 2001) and oxidation of LDL (Sawamura 2004). ADMA is an 
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endogenous inhibitor of eNOS. It competes with L-arginine for its binding site on 
eNOS, thus resulting in decreased NO production. Plasma concentrations of ADMA 
have been reported to be increased in hypercholesterolaemia (Böger et al 1998; 
Böger et al 2003) and ADMA is considered to be both a marker and risk factor of ED 
(Böger et al 1998). 
 
In addition to scavenging NO, excess O2
- modifies LDL cholesterol to oxidized LDL 
(ox-LDL) which plays a major role in atherogenesis. ox-LDL has been reported to 
promote ET-1 production (Boulanger et al 1992), expression of adhesion molecules 
and chemoattractants, and VSMC migration and proliferation (Sawamura 2004). 
Furthermore, ox-LDL is engulfed by macrophages forming foam cells which adhere 
to the vessel wall initiating an atherosclerotic plaque (Sawamura 2004). Both LDL 
and ox-LDL have been shown to increase the activity of S-adenosylmethionine-
dependent methyltransferases, which lead to increased ADMA synthesis. Therefore, 
LDL and ox-LDL maybe be accountable for the increased plasma levels of ADMA in 
hypercholesterolaemia (Warnholtz et al 2001).  LDL or ox-LDL may also upregulate 
caveolin-1 synthesis and thus inhibit eNOS activity (Davignon and Ganz 2004; 
Hamburg & Vita 2005). 
 
1.3.1.3 Hypertension 
Patients with hypertension demonstrate blunted forearm blood flow in response to 
stimuli such as acetylcholine and bradykinin (Tang & Vanhoutte 2010). Increased 
production of ROS and endothelial derived contracting factors (EDCFs) such as   
ET-1, angiotensin II, PGH2 and TXA2, and thus decreased NO bioavailability are all 
observed in hypertension (Versari et al 2009; Tang & Vanhoutte 2010). Shear stress 
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is known to be one of the important mechanisms of inducing NO-mediated 
vasodilation in both micro- and macrovasculature. However, this response is not 
observed in hypertension. Paniagua et al (2001) reported diminished vasodilation in 
response to shear stress in the microvasculature of hypertensive patients. In addition 
to this, Iaccarino et al (2004) found abolished PKB/Akt dependent-activation of 
eNOS due to mislocalisation of PKB/Akt to the plasma membranes in a model of 
spontaneously hypertensive rats (SHR). 
 
1.3.1.4 Smoking 
Tobacco smokers exhibit impaired flow mediated vasodilation, decreased NO 
bioavailability, and increased levels of ox-LDL (Puranik & Celermajer 2003).  Passive 
smoking is also implicated in impairment of endothelial function (Barnoya & Glantz 
2005; Puranik & Celermajer 2003). It appears that the harmful effects of smoking on 
the endothelial cells are dose-dependent and reversible upon smoking cessation 
(Puranik & Celermajer 2003). Oxidative stress appears to be the major link between 
smoking and ED (Puranik & Celermajer 2003; Barnoya & Glantz 2005; Burke & 
FitzGerald 2003). Cigarette smoke is rich in free radicals and directly delivers free 
radicals into the body. Besides being the supplier of free radicals, cigarette smoke 
facilitates endogenous release of ROS via activation of inflammatory cells (Burke & 
FitzGerald 2003; Antoniades et al 2008). Smokers have also been shown to have 
increased platelet activation and circulating levels of fibrinogen, factors that 
predispose to thrombogenesis (Burke & FitzGerald 2003). Furthermore, smoking has 
been reported to decrease the levels of high density lipoprotein (HDL) cholesterol, 
which is known to have anti-atherosclerotic properties (Puranik & Celermajer 2003).  
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1.3.1.5 Aging 
Increasing age has been recognised as one of the factors that predisposes to ED 
(Katusic 2007; Herrera et al 2010). With aging, the ability of the endothelium to 
produce NO is reduced (Vanhoutte 2002). Furthermore, some studies have reported 
reduced expression and activity of eNOS as well decreased expression of sGC on 
VSMCs and its activity in older animals (Vanhoutte 2002). In addition to the 
decreased NO production, other EDRFs (prostacyclin and EDHF) are also reduced 
(Vanhoutte 2002), while EDCFs such as ET-1 and COX-derived prostanoids, and 
ROS production are increased (Herrera et al 2010; Vanhoutte 2002). Plasma levels 
of ADMA also rise with aging (Vanhoutte 2002). 
 
One of the mechanisms contributing to reduced NO in aging may be the increased 
activity of arginase I (Katusic 2007; Herrera et al 2010). Arginase I is an enzyme that 
catalyses conversion of L-arginine to L-ornithine and urea, and it thus competes with 
eNOS for L-arginine (Katusic 2007). Thus the increased activity of this enzyme as 
observed with advancing age may result in ED (Katusic 2007; Herrera et al 2010). 
Clearly the balance between EDRFs and EDCFs is lost with advancing age, 
establishing aging as a risk factor for cardiovascular disease. Moreover, aging is 
often associated with conditions such as diabetes, hypertension, and 
hypercholesterolaemia further exacerbating the risk of developing atherosclerosis 
and thus cardiovascular diseases (Herrera et al 2010).  
 
1.3.2 Proposed mechanisms of ED 
Oxidative stress appears to be the common ED inducing pathway in all of the above 
discussed risk factors. According to the literature, cardiovascular risk factors are 
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associated with upregulation of sources of ROS, especially NADPH oxidase 
(Forstermann & Munzel 2006; Chhabra 2009). However other sources of ROS such 
as xanthine oxidase, COX and mitochondria are not completely sidelined (Guzik et al 
2002). In fact, eNOS itself is a potential ROS generator when uncoupled 
(Forstermann & Munzel 2006). Damaging mechanisms of oxidative stress include 
increasing VSMC proliferation, endothelial cell apoptosis, and increased expression 
and activity of matrix metalloproteinases (Pennathur & Heinecke 2007). 
 
Oxidative stress comprises increased rates of oxidant production and decreased 
levels of antioxidants such as superoxide dismutase (SOD), vitamin C and E, etc. 
(Pennathur & Heinecke 2007). Under physiological conditions, the enzyme SOD 
regulates the levels of O2
- (Landmesser et al 2006). However, upregulated 
generation of O2
- overwhelms the defensive mechanisms of this enzyme, leaving O2
- 
free to react with other molecules such as NO (Landmesser et al 2006). O2
- is 
implicated in direct induction of ED by scavenging of NO leading to production of 
potentially harmful peroxynitrite (Yokoyama 2004). In fact, the reaction between O2
- 
and NO has been reported to occur much faster (rate constant=6.7 x 109 m/s-1) than 
that of dismutation of O2
- by SOD (rate constant=2.0 x 109 m/s-1) (Huang 2003). High 
levels of peroxynitrite are injurious to the cells, oxidatively damaging DNA, lipids and 
proteins. In addition to being cytotoxic, peroxynitrite damages the intricate eNOS 
structure leading to eNOS uncoupling (Kuzkaya et al 2003).  
 
Peroxynitrite has been reported to oxidise the essential cofactor of eNOS, BH4 to its 
inactive form trihydrobiopterin radical (BH3
-) which leads to uncoupling of eNOS [Fig. 
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1.10A] (Katusic 2001; Forstermann & Munzel 2006; Kuzkaya et al 2003). 
Furthermore, peroxynitrite may oxidize the zinc thiolate cluster resulting in the loss of 
the zinc ion and formation of disulfide bonds between the monomers, and thus 
disruption of the binding site for BH4 and L-arginine [Fig. 1.10B] (Forstermann & 
Munzel 2006; Zou et al 2002 (a)). Some studies have reported that BH4 is only 
oxidized at 10 to 100-fold higher levels of peroxynitrite than required to oxidize the 
zinc thiolate cluster. This suggests that oxidation of the zinc thiolate cluster may be 
the chief mechanism of uncoupling eNOS rather than oxidation of BH4 (Forstermann 
& Munzel 2006; Zou et al 2002 (a)). Vitamin C is able to recycle BH3
- to BH4 
(Kuzkaya et al 2003; Katusic 2001) and supplementation with BH4 has been reported 
to restore endothelial function in conditions such as insulin resistance, 
hypercholesterolaemia (Katusic 2001), diabetes mellitus, and essential hypertension, 
as well as in chronic smokers (Forstermann & Munzel 2006). 
 
In view of the decreased NO bioavailability observed in ED, one would expect that 
eNOS expression will also be decreased. However, in most cases, cardiovascular 
risk factors are associated with augmented eNOS expression which may be 
attributable to surplus hydrogen peroxide (H2O2) observed in oxidative stress (Li H et 
al 2002). The ability of H2O2 to increase eNOS expression via transcriptional and 
post-transcriptional mechanisms has been shown by several studies (Drummond et 
al 2000). However, despite increased eNOS expression, there is a paradoxical 
marked decrease in NO production, associated with an increase in O2
- production 
due to eNOS uncoupling.  
Zou et al (2002) (b) observed decreased phosphorylation and activity of PKB/Akt in 
bovine aortic endothelial cells following treatment with peroxynitrite. They further 
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found that, peroxynitrite increased AMPK-mediated phosphorylation of eNOS. 
However, the increased eNOS phosphorylation was not associated with NO but with 
O2
- production. 
Therefore, during conditions of oxidative stress, eNOS deviates from its role of being 
an essential regulator of the functioning of the cardiovascular system to being an O2
- 
releasing enzyme. Peroxynitrite appears to play a major role in eNOS uncoupling. 
Uncoupled eNOS synthesises O2
- at the expense of NO, further aggravating 
oxidative stress. 
 
Figure 1.10A: Peroxynitrite and eNOS function. Peroxynitrite (ONOO
-
) oxidises BH4 into its inactive 
form BH2 and therefore uncoupling eNOS. (Copied from Fostermann & Munzel 2006) 
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Figure 1.10B: Peroxynitrite and eNOS function. Alternatively, peroxynitrite oxidises the zinc thiolate 
cluster resulting in the loss of zinc and formation of disulfide bonds between monomers, and therefore 
disruption of the BH4 and L-arginine binding site, and ultimately eNOS uncoupling. (Copied from 
Fostermann & Munzel 2006) 
 
 
Inflammation is another common underlying mechanism of ED (Libby et al 2002). 
Under physiological conditions, the endothelium regulates vascular inflammation 
(including expression of adhesion molecules and leukocyte adhesion) via the release 
of NO (Osto & Cosentino 2010). It is therefore more likely that ED will promote 
sustained vascular inflammation which is detrimental to the vascular system. 
However, several studies have reported that inflammation also promotes ED and it is 
thus recognised as a novel risk factor for cardiovascular diseases (Szmitko et al 
2003; Libby et al 2002). There seems to be a causal relationship between oxidative 
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stress and inflammation. Oxidative stress may amplify vascular inflammation 
signalling pathways (Madamanchi et al 2005) and inflammatory cells release O2
-. 
Inflammation is often associated with overexpression of inflammatory cytokines such 
as tumour necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1). These inflammatory 
cytokines in turn prompt endothelial cells or macrophages to release adhesion 
molecules such as VCAM-1 and ICAM-1, MCP-1, interleukin-6 (IL-6) resulting in a 
state of endothelial activation (Blake & Ridker 2001). 
 
The role of TNF-α in ED is now well appreciated. TNF- α has been associated with 
cardiovascular diseases such as acute myocardial infarction, chronic heart failure, 
atherosclerosis, myocarditis, etc. (Meldrum 1998). TNF-α levels are also significantly 
correlated with obesity which is an independent risk factor of ED (Fain et al 2004). 
This inflammatory cytokine has been reported to promote ROS formation via NADPH 
oxidase, xanthine oxidase, etc. (Zhang et al 2009). For example, Gao et al (2007) 
reported that TNF-α induces ED via increased NADPH oxidase activity in coronary 
arterioles of type 2 diabetic mice. In addition, TNF-α has been implicated in the 
downregulation of eNOS expression by accelerating eNOS mRNA degradation 
(Hamburg & Vita 2005, Stenvinkel 2001; Zhang et al 2009). According to Zhang et al 
(2006), ED observed in myocardial ischaemia-reperfusion injury may be attributable 
to increased TNF-α expression via enhancement of xanthine oxidase activity.  
 
For a summary of proposed mechanisms of ED, please refer to figure 1.11. 
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Figure 1.11: A summary of proposed mechanisms of ED. 
 
1.3.3 Markers of ED 
1.3.3.1 Reduction of NO bioavailability 
Reduction in endothelial-derived NO production or bioavailability represents a key 
step in pathogenesis of cardiovascular diseases. Indeed, reduced NO bioavailability 
is the hallmark of ED (Davignon and Ganz 2004). The major NO reducing pathways 
include scavenging of NO by O2
-, decreased eNOS expression or activation and 
eNOS uncoupling. Elevated TNF-α and ox-LDL have been reported to decrease 
eNOS expression by accelerating eNOS mRNA degradation (Hamburg & Vita 2005; 
Stenvinkel 2001). eNOS activation is another critical determinant of NO 
bioavailability. However, a risk factor such as hyperglycaemia is associated with 
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PKC activation which phosphorylates eNOS at its inhibitory site, Thr 495, thus 
inhibiting its activity (Avogaro et al 2008). 
 
1.3.3.2 NADPH oxidase upregulation 
Under physiological conditions, vascular NADPH oxidase slowly produces low 
physiological amounts of ROS that participate in cellular signalling (Griendling et al 
2000). However, upregulated NADPH oxidase expression as observed in a variety of 
cardiovascular risk factors is implicated in atherogenesis. Vascular NADPH oxidase 
is characterized by two membrane bound subunits, p22phox and gp91phox, and two 
cytosolic subunits p67phox, p47phox and a protein rac1 or sometimes rac2 
depending on cell type of expression (Griendling et al 2000; Brandes & Kreuzer 
2005). Each of these subunits is employed in research to determine expression and 
activity of the NADPH oxidase enzymes, and thus an indicator of oxidative stress. 
 
Prolonged treatment with angiotensin II in rats has been reported to increase 
expression of p22phox mRNA whereas TNF-α increased expression of p22phox 
mRNA in VSMCs (Griendling et al 2000). On the other hand, Li J-M et al (2002) 
reported increased p47phox-dependent ROS generation following treatment with 
TNF-α in coronary microvascular endothelial cells. 
 
1.3.3.3 Nitrotyrosine upregulation 
In addition to uncoupling the eNOS enzyme, peroxynitrite undergoes protonation to 
form peroxynitrous acid or combine with carbon dioxide (CO2) to form nitroso-
peroxocarboxylate, both of which yield tyrosine-nitrating compounds (Souza et al 
2008; Hurst 2002). Via formation of these compounds, peroxynitrite leads to nitration 
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of tyrosine residues of proteins forming nitrotyrosine. Tyrosine nitration involves 
addition of a nitro group (NO2) on the aromatic ring of tyrosine residues (Pacher et al 
2007). Under normal conditions, low levels of free or protein-bound nitrotyrosine are 
detectable which may indicate low levels of oxidants and nitrating species produced 
during physiological processes. However, significant nitrotyrosine upregulation is 
observed in conditions that are associated with nitroxidative stress such as 
inflammation, cardiovascular disease, neurodegenerative disorders, etc (Souza et al 
2008). Tyrosine nitration may modify the structure and function of proteins, leading to 
alterations in catalytic activity of enzymes, production of antigenic epitopes, and 
impaired cell signal transduction (Pacher et al 2007). 
 
1.3.3.4 Circulating endothelial cells  
Circulating endothelial cells (CECs), which are mature cells that have detached from 
the endothelium (Boos et al 2006), represents a new biomarker of endothelial injury 
(Erdbruegger et al 2006). In a healthy person, the endothelium is constantly 
refurbished at a replication rate of < 1 % and levels of CECs are very low 
(Erdbruegger et al 2006). Studies using a flow activated cell sorter (FACS) isolation 
technique reported CECs ranging from 50 - 7,900 cells/ml in healthy individuals and 
up to 39,100 cells/ml in individuals with vascular diseases. On the other hand, 
immunomagnetic studies revealed a range of only 0-10 CECs/ml in healthy 
individuals (Erdbruegger et al 2006). However, despite the methodological disparities 
in the overall cell number, both these techniques reveal lower levels of CECs in 
healthy individuals. 
 
63 
 
Increased levels of CECs are associated with ED, cardiovascular diseases and a 
variety of other diseases (Boos et al 2006; Erdbruegger et al 2006). Potential 
mechanisms underlying endothelial cell detachment may be mechanical injury, 
action of proteases and/or cytokines, defective endothelial cell adhesion to ECM, 
cellular apoptosis and actions of cardiovascular risk factors (Boos et al 2006; 
Erdbruegger et al 2006).  
 
1.3.3.5 ADMA 
ADMA has emerged as both a marker and a mediator of ED (Böger et al 2003). 
ADMA is endogenously synthesised via methylation of arginine residues in the 
nuclear proteins (Landim et al 2009).  ADMA competitively inhibits eNOS resulting in 
decreased NO production, and may induce eNOS uncoupling. Synthesis of ADMA is 
catalysed by protein arginine methyltransferases (PRMTs) and its degradation is 
catalysed by dimethylarginine dimethylaminohydrolases (DDAH) (Landim et al 2009; 
Sydow & Munzel 2003). The latter is often decreased in a variety of cardiovascular 
disease and thus leading to upregulation of ADMA. For example, treatment of 
endothelial cells with TNF-α, ox-LDL and glucose has been reported to diminish the 
activity of DDAH (Landim et al 2009; Sydow & Munzel 2003). Furthermore, PRMTs 
and DDAH are ROS-sensitive and thus activity of the latter is impaired whereas 
activity of the former is increased in conditions of oxidative stress (Sydow & Munzel 
2003). 
 
Increased plasma levels of ADMA have been documented in patients with conditions 
such as hyperlipidaemia, hypertension, coronary artery disease, stroke, end-stage 
renal disease, etc. (Sydow & Munzel 2003). Since ADMA induces eNOS uncoupling 
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and reduces NO production, it may contribute to the pathogenesis of cardiovascular 
diseases (Landim et al 2009; Sydow & Munzel 2003).  
 
1.4 ED in atherosclerosis 
ED has emerged as a useful prognostic tool for atherosclerosis and ultimately 
cardiovascular disease (Yang & Ming 2006). In fact, ED plays a major role in the 
development of atherosclerosis (Yang & Ming 2006). An intact endothelium is almost 
impermeable and does not promote leukocyte adherence and invasion, or platelet 
aggregation and adherence (Libby et al 2002). However, ED is often associated with 
enhanced endothelial permeability, upregulated pro-inflammatory cytokines and, 
expression of adhesion molecules such as VCAM-1 and ICAM-1 which facilitate 
leukocyte adhesion to the endothelium (Libby et al 2002). Leukocyte adhesion 
represents one of the first steps in the initiation of atherosclerosis. In fact, authors 
now define atherosclerosis as an inflammatory disease (Lind 2003; Hansson 2009). 
For example, a high fat diet has been associated with recruitment of inflammatory 
cells into the endothelium (Ruberg & Loscalzo 2005).  
 
After adhering to the endothelium, leukocytes (monocytes and lymphocytes) cross 
the endothelium and migrate into the intima (Ruberg & Loscalzo 2005; Osto & 
Cosentino 2010). Upon reaching the intima, monocytes transform into macrophages 
and express receptors that facilitate uptake of lipids. Uptake and accumulation of 
lipids lead to transformation of macrophages into foam cells which initiate an 
atherosclerotic lesion and further enhance release of inflammatory cytokines leading 
to VSMC proliferation and migration into the vessel lumen (Ruberg & Loscalzo 2005; 
Osto & Cosentino 2010). Through these complex mechanisms, a cascade of events, 
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which begins with formation of an early atherosclerotic lesion leading to an advanced 
lesion characterised by a plaque formation, ensues (Ruberg & Loscalzo 2005). At 
this stage, the vessel diameter narrows and blood flow is decreased leading to 
ischaemic conditions (Ruberg & Loscalzo 2005). Progression of this disease is 
eventually associated with cardiac complications such as myocardial infarction.  
 
1.5. ED in cardiac microvascular endothelial cells 
As previously discussed, the endothelium in the heart is categorised into two 
subtypes, namely the coronary vascular endothelium and the cardiac endothelium 
[Fig. 1.2] (Strijdom & Lochner 2009). The coronary vascular endothelium constitutes 
the epicardial coronary arterial and venous endothelial cells, and the intramyocardial 
coronary arterial and venous endothelial cells, whereas the cardiac endothelium 
constitutes the CMECs (> 90 % myocardial capillary derived) and EECs (Strijdom & 
Lochner 2009). It is well known that ED in the coronary circulation is a predecessor 
of atherosclerosis and eventually ischaemic heart disease (IHD) which is a 
consequence of decreased blood flow and thus reduced oxygen supply to the heart 
tissues (Choi et al 2009). To date, most studies investigate models of larger coronary 
blood vessels, however, studies on myocardial capillaries and myocardial capillary-
derived endothelial cells (CMECs) have been neglected and their role in the context 
of ED remains poorly understood.   
 
Taking into consideration the structural and functional endothelial heterogeneity 
across the vascular tree (Aird 2007), endothelial cells in different blood vessels may 
not completely respond in the same manner to injury or insult. Furthermore, due to 
their lack of VSMCs, myocardial capillaries do not dilate nor constrict and therefore 
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the paracrine substances such as NO released by CMECs cannot be involved in 
regulation of vascular tone (Strijdom & Lochner 2009). As mentioned previously, 
CMECs release more NO than do cardiomyocytes (Strijdom et al 2006) in addition to 
other paracrine substances (Shah & MacCarthy 2000).  Considering the strategic 
arrangement and likelihood of paracrine communication between CMECs and 
cardiomyocytes, the putative role of CMEC-derived substances such as NO may be 
to regulate the function and activity of underlying cardiomyocytes in addition to 
maintaining integrity of the cardiac endothelium. In view of this, it is likely that ED in 
CMECs could have a direct harmful impact on the underlying cardiomyocytes. For 
this reason, it is imperative that more studies are undertaken to investigate ED in 
myocardial capillary-derived CMECs, and to explore underlying cellular mechanisms.   
 
1.6. Role of traditional medicinal plants in vascular function and 
possible relevance to ED 
A number of traditional medicinal plants have been reported to demonstrate a wide 
variety of beneficial properties including anti-inflammatory, anti-hypertensive, 
hypoglycaemic, anti-tumorigenic and anti-viral effects (Musabayane et al 2005; Lin et 
al 2009). Plants with medicinal properties include Syzigium cordatum (Hochst.) 
[Myrtaceace] (water berry), Cornus officinalis (cornus), Crataegus pinnatifida 
(hawthorn), Radix ginseng and Olea europaea (olive tree) (Musabayane et al 2005, 
Hsu et al 2006, Lin et al 2009, Xi et al 2009, Sato et al 2007). The triterpenoid, 
oleanolic acid (OA), has recently been isolated from several medicinal plant extracts, 
including Syzigium cordatum, and is proposed to be the candidate bioactive 
compound accountable for many of the beneficial effects observed (Mapanga et al 
2009; Li J et al 2002). OA has also been isolated from olive oil. Thus the low 
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incidence of cardiovascular diseases and cancer associated with high consumption 
of olive oil such as observed in the Mediterranean diet may in part be attributable to 
OA (Rodriguez-Rodriguez et al 2008).  
 
Rodriguez-Rodriguez et al (2008) observed endothelium-dependent vasodilation in 
response to OA in both superior and small mesenteric arteries of rats. This response 
was abolished by incubation with the NOS inhibitor ADMA, suggesting a role for NO 
in OA-induced vasodilation. They further reported that OA treatment resulted in 
phosphorylation of PKB/Akt at residue Ser 473 (thus stimulating its activity) and 
phosphorylation of eNOS at Ser 1177 in human umbilical vein endothelial cells 
(HUVECs). From these observations it appears that OA stimulates eNOS activity via 
the PKB/Akt pathway. Another study reported a COX-2 dependent release of PGI2 
from human coronary smooth muscles following treatment with OA (Martinez-
Gonzalez et al 2008). In addition to its vasoactive properties, OA has been shown to 
lower blood sugar levels in the setting of hyperglycaemia or diabetes mellitus. In a 
study of streptozotocin-induced diabetic rats, Mapanga et al (2009) reported reduced 
mean arterial pressure (MAP) and blood sugar levels, and improved renal function 
following a five week treatment with OA isolated from Syzigium cordatum. The 
reduced MAP was also observed in non-diabetic rats. Moreover, OA has been 
reported to have insulin secretory properties from pancreatic β-cells via stimulation of 
muscarinic M3 receptors by acetylcholine released from cholinergic nerve terminals 
(Hsu et al 2006).  
 
From these observations, OA appears to have some potential in the management of 
diabetes and exert beneficial effects on vascular function. However, further studies 
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investigating cellular mechanisms involved in OA actions are required, particularly in 
the context of ED and myocardial capillary-derived endothelial cells.  
 
1.7 Rationale, Motivation and Aim 
1.7.1 Rationale and motivation 
ED represents one of the first steps in the initiation of IHD and it is widely accepted 
as a very useful prognostic tool in predicting the development of atherosclerosis 
(Yang & Ming 2006). Given its reversibility, ED may signify an important therapeutic 
target in the prevention of atherosclerosis and hence cardiovascular disease. For 
this reason, ED has received much attention in research over the years and its role 
in the large coronary vessels is very well defined. However, despite a vast amount of 
publications on ED to date, its role and mechanisms in myocardial capillary-derived 
CMECs is not clear.  
 
CMECs possess a special functional characteristic in that they line the myocardial 
capillaries, which due to their lack of VSMCs are unable to dilate or constrict. Each 
cardiomyocyte is surrounded by at least 3-4 capillaries and the intercapillary distance 
between each cardiomyocyte is estimated be around 15-50 µm. This strategic 
arrangement allows for optimal paracrine communication between CMECs and 
cardiomyocytes (Brutsaert 2003; Strijdom & Lochner 2009).  CMEC-derived factors 
such as NO therefore principally regulate the function and activity of cardiomyocytes 
and are not involved in the regulation of vascular tone such as their endothelial cell 
counterparts in larger, muscular arteries. In view of this, cardiac microvascular ED 
could have significant effects on the function of cardiomyocytes. Interestingly, the 
role and mechanism of ED in CMECs have not been readily explored. As per 
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previous reports, ED may play a major role in potentiating IHD. According to Nishida 
et al (1993), hypertension and diabetes associated ED primarily targets the 
microcirculation of the heart. CMECs represent about 90 % of the total endothelial 
cells in the heart (Piper et al 1990). Furthermore, cultures of microvascular 
endothelial cells are compulsory for a comprehensive investigation of cellular 
metabolism and physiological function (Piper et al 1990). However, when exploring 
the mechanisms of ED, in vitro models of CMECs have been neglected and 
endothelial cells obtained from larger coronary vascular vessels have taken 
preference. This is probably due to the fact that they are easier to isolate and culture 
and to the (incorrect) notion that all endothelial cells exhibit the same cellular 
mechanisms thus overlooking their functional and structural heterogeneity (for review 
see Aird 2007). In this study, we attempt to address the lack of available data as 
described above by investigating ED in a model of cultured endothelial cells obtained 
from myocardial capillaries.  
 
Anecdotal evidence supporting the cardioprotective, renoprotective and anti-diabetic 
effects of traditional medicinal plants is vast but scientific investigations to validate 
such assertions and explore underlying mechanisms are relatively rare. Musabayane 
and co-workers (2005) have recently isolated OA as the bioactive compound in leaf 
extracts from Syzigium cordatum, a widely used medicinal plant in Southern Africa. 
OA has been shown to have hypoglycaemic, hypotensive and vasodilatory effects, 
and insulin secretory properties (Mapanga et al 2009; Rodriguez-Rodriguez et al 
2008; Hsu et al 2006). However, to our knowledge, the role of OA in ED, and 
CMECs in particular, has not been investigated. In an attempt to explore the putative 
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therapeutic properties of OA on ED, we aimed to investigate the role of OA in 
CMECs during physiological conditions and in the context of ED.  
 
1.7.2 Aims 
Given the lack of available data on ED in myocardial capillary-derived CMECs, this 
study is explorative and observational, and therefore not hypothesis-driven. 
 
In this study we aim to: 
 Establish an in vitro model of ED in cultured myocardial capillary-derived 
CMECs by developing protocols for the induction of ED. 
 Asses ED induction by measurement of the following biomarkers:                   
(i) intracellular NO production, (ii) O2
- production, (iii) nitrotyrosine expression 
and (iv) NADPH oxidase expression. 
 Investigate underlying cellular mechanisms by measuring and comparing 
eNOS and PKB/Akt expression and activation in control and dysfunctional 
CMECs. 
 Investigate the effects of OA derived from traditional medicinal plant extracts, 
in particular Syzigium cordatum (Hochst.) [Myrtaceace], in both control and 
dysfunctional CMECs.  
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 Chapter 2: Materials and methods 
 
2.1 Materials 
Endothelial cell-specific trypsin (500 BAEE units trypsin / 180 µg EDTA.4Na / ml in 
Dulbecco‟s phosphate buffered saline (PBS)), propidium iodide (PI) and human 
recombinant TNF-α were obtained from Sigma Chemical Co (St Louis, Mo, USA); 
4,5-diaminofluorescein-2/diacetate (DAF-2/DA) was purchased from Calbiochem 
(San Diego, CA, USA); alexa fluor® 647 annexin V was obtained from BioLegend 
(San Diego, CA, USA); dihydroethidium (DHE) was obtained from Invitrogen 
(Carlsbad, CA) and fibronectin from Roche (Roche Diagnostics, Randburg, RSA); 
eNOS, phospho-eNOS (Ser 1177), PKB/Akt, phospho PKB/Akt (Ser 473) antibodies 
were obtained from Cell Signaling Technologies (Beverly, MA, USA), and p22-phox 
and nitrotyrosine antibodies from Santa Cruz Biotechnologies (Santa Cruz, CA, 
USA). All other chemicals were of Analar grade and were purchased from Merck 
(Cape Town, RSA). 
 
2.2 Cell cultures and endothelial cell purity 
Adult rat CMECs were purchased commercially from VEC technologies (Rensselaer, 
New York, USA). The microvascular endothelial cell harvesting technique followed 
by the company has previously been described (Nishida et al 1993; Piper et al 
1990), and ensures the highest possible myocardial capillary-derived CMEC yield, 
precluding contamination by other endothelial cell types. Cells were received in 25 or 
75 ml fibronectin coated tissue culture flasks and grown in microvascular endothelial 
growth medium [EGM] (Clonetics EGM-2MV; Lonza, Walkersville, MD) until they 
were fully confluent. The basal growth medium was supplemented with 10 % fetal 
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bovine serum [FBS] (Highveld Biological, RSA), standard endothelial growth factors, 
ascorbic acid and antibiotics. The cells were grown in a standard tissue culture 
incubator at an atmospheric composition of 21 % oxygen, 5 % carbon dioxide, 40-60 
% humidity and temperature maintained at 37 ºC. Confluent cells (cells evenly 
distributed across flask and completely covering the flask) were removed from 
culture by addition of trypsin, resuspended in growth medium and subcultured to the 
next generation in a 1:2 ratio in 35 mm fibronectin coated petri dishes for 
experimental purposes.  
 
Microscopic examination of cultured CMECs revealed characteristic “cobblestone” 
monolayer morphology, a distinct trait of endothelial cells in culture, thus confirming 
morphological purity (Piper et al 1990) [fig. 2.1]. Furthermore, functional purity tests 
were performed by measuring CMEC uptake of fluorescently labelled 1,1-
dioctadecyl-3,3,3‟,3‟-tetramethylindocarbocyanine perchlorate-acetylated-low density 
lipoprotein [Dil-ac-LDL] (Biomed Technologies, Stoughton, MA), a probe which is 
specific for endothelial cells (Nishida et al 1993, Piper et al 1990). Briefly CMECs 
were incubated with 10 ug/ml Dil-ac-LDL at 37ºC for 4 hours. The probe was 
subsequently washed out, and cells were removed from culture by trypsinisation, 
resuspended in PBS and analysed by FACS in the FL2-H channel.  A high 
fluorescence uptake (80-100%) indicates endothelial cell purity, and no experiments 
were conducted on CMEC subcultures with < 80 % purity [fig. 2.2].  
 
 
Subcultures of the 4th to 7th generations demonstrated optimal endothelial cell purity 
and were thus used for experimental purposes. Upon confluency, the cell cycle is 
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arrested at the G0 phase due to cell-to-cell contact and thus cell proliferation (mitotic 
activity) ceases, thereby minimising possible cell cycle variability when evaluating 
experimental results (Vinals & Pouyssegur 1999). Only confluent cultures were thus 
used for experimental purposes. Petri dishes were randomly assigned to respective 
control and experimental groups. Each experiment was repeated three times and the 
sample size varied from n = 6-12. 
 
 
Figure 2.1: Micrograph of CMECs showing a characteristic “cobblestone” morphology in culture (10x 
magnification; Carl Zeiss inverted microscope, West Germany) 
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Figure 2.2: A typical histogram representation of autofluorescence (probe-free control) (blue) and Dil-
ac-LDL fluorescence (purple). 
 
2.3 Flow cytometry 
Flow cytometric analysis of all fluorescent probes was performed by a flow activated 
cell sorter (FACS) [Becton-Dickinson FACSCalibur, Franklin Lakes, NJ], using 
protocols previously developed in our laboratory (Strijdom et al 2004 & 2006). A total 
of 5 000-10 000 events were routinely analysed per sample and a final cell 
population of interest was selected by placing a gate on control samples according to 
their side scatter (cell granularity) and forward scatter (cell size) [Fig. 2.3A & B], 
thereby excluding debris and non-cellular particles. Fluorescence data were 
analysed with Cellquest Pro® version 5.2.1 software (Becton-Dickson and Co, San 
Jose, CA). Unless stated otherwise, all fluorescence data are expressed as follows: 
(i) Mean fluorescence intensity expressed as % of control (control adjusted to       
100 %), and (ii) % fluorescent cells of total gated population. 
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Figure 2.3A: A representative diagrammatic representation of a dot plot of a CMEC sample showing 
the side scatter (Y axis) which measures cell granularity and forward scatter (X axis) plot which 
measures cell size. The population of interest subjected to analysis is selected by placing a gate. 
 
 
Figure 2.3B: A density plot of the same sample showing the side and forward scatter plot, and the 
gated population of interest. 
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2.4 Induction of endothelial dysfunction 
In order to establish an in vitro model of ED, two different cardiovascular risk factors 
that are clinically associated with the development of ED, were simulated, namely 
hyperglycaemia and inflammation. Hyperglycaemia was achieved by incubating 
CMECs with 25 mM D-glucose (Merck chemicals, Gauteng, RSA) for 24 hours and 
inflammation simulated by incubating CMECs with the pro-inflammatory cytokine, 
TNF-α (1 ng/ml for 24 hours and 5 ng/ml for 6 or 24 hours). For diagrammatic 
representation of the experimental groups and protocols, please refer to fig. 2.4. The 
control samples were incubated with fresh, untreated medium for the same 
incubation period corresponding to the experimental groups.  
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Figure 2.4: Experimental groups and protocols for ED induction. 
Legend: 
* Administration of fluorescent probes / sample preparation for Western blot 
analysis. 
§   PI / annexin V incubation (15 min). 
●   DAF-2/DA incubation (2 hours). 
♦   DHE incubation (2 hours). 
¤   Sample preparation for FACS analysis of PI / annexin V fluorescence. 
¥   Sample preparation for FACS analysis of DAF-2/DA fluorescence (or 
DHE fluorescence in the case of 5 ng/ml TNF-α 24 over hours samples). 
1 ng/ml TNF-α 
5 ng/ml TNF-α 
5 ng/ml TNF-α 
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2.4.1 Cell viability tests 
At the end of the experimental incubation period, cell viability was confirmed, where 
indicated, by treatment of cells with 5 µM of PI and 5 µM annexin V (conjugated with 
Alexa Fluor® 647) for 15 minutes [fig. 2.4] prior to FACS analysis in the FL2-H and 
FL4-H channels respectively [fig. 2.5A & B]. Briefly, cells were removed from culture 
by trypisinisation, washed sequentially in staining and binding buffer (BioLegend) 
and subsequently treated with 5 µM of PI and annexin V, and incubated at room 
temperature in the dark for 15 min, followed by FACS analysis. Cell membrane 
permeability (loss of membrane integrity) grants the PI probe entrance into the cell 
which subsequently stains the nucleus. Therefore, cells demonstrating PI uptake 
represent a non-viable (necrotic) cell population. Apoptotic cells are identified by 
binding of annexin V to phosphatidylserine protein, which in healthy cells is  normally 
located on the intracellular surface of the plasma membrane but translocates to the 
external surface of the plasma membrane during apoptosis. PI and Annexin V 
staining therefore distinguishes between cells undergoing necrosis and apoptosis 
respectively [fig. 2.6] (Wilkins et al 2002).  
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Figure 2.5: A. A histogram depicting flow cytometric analysis of PI fluorescence in channel FL2-H. 
The second peak represents cells that positively stained with the PI probe and hence regarded as 
non-viable (necrotic). B. Flow cytometric analysis of Annexin V fluorescence in channel FL4-H with 
the second peak representative of cells that positively stained with the Annexin V and are thus 
considered non-viable (apoptotic). 
 
 
 
 
 
 
 
 
 
A B 
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Figure 2.6: A dot plot illustrating PI fluorescence (FL2-H) and annexin V fluorescence (FL4-H), which 
allows the investigator to distinguish between apoptotic cells (lower right quadrant: annexin V staining 
positive, 7.3 % of the total gated population in the above sample) and necrotic cells (upper right 
quadrant: PI staining positive,18.5 % of the total gated population in the above sample). Viable cells 
(PI and annexin V negative, 74 % of the total gated population in the above sample) appear in the 
lower left quadrant. 
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2.4.2 NO production measurements 
The measurement of intracellular NO levels was used as an end-point to verify 
whether ED induction was successfully achieved. Intracellular levels of NO were 
directly measured using the NO-specific DAF-2/DA fluorescent probe as previously 
described by Strijdom et al (2004 & 2006). Upon reacting with NO, DAF-2/DA is 
oxidised to diaminofluorescein-triazol (DAF-2T) which emits a green fluorescence 
analysed in the FL1-H channel by FACS [fig. 2.7]. At the end of the ED induction 
period, cells were washed with PBS and incubated with 10 µM DAF-2/DA at 37 ºC 
for 2 hours. After 2 hours, DAF-2/DA was washed out and cells removed from culture 
by trypisinisation and resuspended in probe-free PBS for FACS analysis [fig. 2.4]. All 
experiments included a probe-free absolute control sample (to determine 
autofluorescence) and probe-containing control samples [fig. 2.7]. A significant 
increase in baseline fluorescence in probe-containing control samples confirms 
proper DAF-2DA uptake by the cells, as demonstrated in fig. 2.7.  
 
Figure 2.7: A histogram representation of autofluorescence of the cells (a probe-free control, used as 
an absolute control) and DAF-2/DA fluorescence (DAF-2/DA treated control) in the FL1-H channel. 
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2.4.3 Superoxide measurements 
We measured O2
- production in CMECs using a superoxide-sensitive probe, DHE. 
After 24 hours of ED induction, cells were washed with PBS and treated with 5 µM 
DHE in PBS and incubated at 37 ºC for 2 hours as per previous descriptions 
(Navarro-Antolin et al 2001) [fig. 2.4]. After 2 hours, probe-containing PBS was 
washed out and cells removed from culture by trypisinisation. Cells were 
resuspended in probe-free PBS and DHE fluorescence was analysed by FACS in 
channel FL2-H.  
 
2.4.4 Protein expression and phosphorylation measurements 
Total and phosphorylated (activated) eNOS and PKB / Akt, and nitrotyrosine and 
NADPH oxidase protein expression were measured by Western blot analysis. The 
membrane bound NADPH oxidase subunit, p22-phox, was used to quantify NADPH 
oxidase expression (Griendling et al 2000). β-tubulin was also measured to confirm  
equal protein loading in all samples. To extract protein, cells were lysed in a lysis 
buffer that comprised: 20 mM Tris; 1mM EGTA; 150 mM NaCl; 1mM β-
glycerophosphate; 1 mM sodium orthovanadate; 2.5 mM tetra-sodium diphosphate; 
1 mM PMSF; 0.1 % sodium dodecylsulfate (SDS); 10 µg/ml aprotinin; 10 µg/ml 
leupeptinin; 50 nM NaF and 1 % triton-X100. After lysis, cells were subjected to 
sonication, after which cell lysate protein of 50 µg / 10 µl was obtained.  Cell lysate 
proteins of equal amounts were subsequently loaded onto a 7.5 % (for eNOS, 
PKB/Akt, and β-tubulin); 10 % (for nitrotyrosine) and 12 % (for p22-phox) SDS-
polyacrylamide gel and transferred onto PVDF membrane (immobilon™-P, from 
Millipore). Non-specific binding sites on membranes were blocked with 5 % fat-free 
milk in Tris-buffered saline, 0.1 % tween-20. 
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Following Western blotting, membranes were probed with the specific rabbit 
polyclonal primary antibodies (anti-eNOS, anti-phospho eNOS (Ser 1177), anti- 
PKB/Akt, anti-phospho PKB/Akt (Ser 473), anti-β-tubulin) [Cell Signalling 
Technology, Beverly, MA, USA], and (anti-p22-phox and anti-nitrotyrosine) [Santa 
Cruz Biotechnologies, Santa Cruz, CA, USA]. The membranes were subsequently 
exposed to the secondary antibody, horseradish peroxidise-linked anti-rabbit IgG 
(Amersham, Buckinghamshire, UK). The ECLTM system was employed to observe 
the immunoreactions and films were analysed by densitomentry (UN-SCAN-IT, Silk 
Scientific, Orem, UT, USA). All Western blot data were expressed as ratio of control 
with control adjusted to 1. 
 
 
2.5 Plant extracts studies  
2.5.1 OA isolation 
OA powder extract was kindly supplied by Prof Cephas Musabayane (University of 
KwaZulu-Natal, South Africa). The leaves of Syzigium cordatum (Hochst.) 
[Myrtaceae] were obtained from the Durban region (KwaZulu-Natal). Professor H 
Baijnath, former chief taxonomist/ curator at the University of KwaZulu-Natal, verified 
the identity of the plant.  
 
The leaves were air-dried and pulverised into fine powder. The powder was 
consecutively extracted three times at 24 hour intervals with three litres of hexane, 
dichloromethane, ethyl acetate and methanol as previously described (Mapanga et 
al 2009). The crude acetyl acetate extract (ethyl acetate-solubles; EAS) contained 
the bioactive compound as has been previously verified by Musabayane et al (2005) 
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and Samova et al (2003) and was further purified. The purified EAS subsequently 
underwent a series of open column chromatography steps, ultimately yielding OA as 
a white powder as described previously (Mapanga et al 2009). The structure of OA 
was ascertained by H and C-NMR (1D and 2D) spectroscopy. The purity of OA was 
99 % when compared to spectral data available in existing literature based on the 
chemical and physicochemical properties (Mapanga et al 2009).  
 
2.5.2 Pilot studies to assess the effects of OA on CMECs 
Confluent CMECs were treated with either 30 µM or 40 µM OA dissolved in dimethyl 
sulfoxide (DMSO) for 5 and 20 min [fig. 2.8]. The vehicle control samples were 
treated with corresponding volumes of DMSO only and the controls received fresh 
medium only. At the end of each incubation period, NO production (DAF-2/DA) and 
cell viability (PI and Annexin V) were measured using methods described in previous 
sections.  
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Figure 2.8: Experimental groups for pilot studies to asses effects OA on CMECs. 
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Legend: 
*  Administration of fluorescent probes 
§   PI / annexin V incubation (15 min) 
●   DAF-2/DA incubation (2 hours) 
¤   Sample preparation for FACS analysis PI / annexin V fluorescence 
¥   Sample preparation for FACS analysis DAF-2/DA fluorescence 
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2.5.3 The effects of OA in ED 
2.5.3.1 Cell viability and NO measurements 
To determine the effects of OA in dysfunctional CMECs, confluent CMECs were pre-
treated with 40 µM OA 1 hour prior to ED induction (5 ng/ml TNF-α for 24 hours). 
The experiments consisted of four groups, namely (i) untreated controls, (ii) OA 
treated cells, (iii) TNF-α treated cells (ED group), and (iv) TNF-α + OA treated cells   
(OA + ED group) [fig. 2.9]. Following the incubation period, NO production and cell 
viability were determined. Separate studies showed that administration of the vehicle 
for OA (DMSO) for 24 hours had no significant effect on NO production or cell 
viability (data not shown). 
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Figure 2.9: Experimental groups and protocols for OA investigations in normal and dysfunctional 
CMECs.  
 
 
 
 
 
 
 
 
 
Legend: 
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analysis. 
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2.5.3.2 Protein expression and phosphorylation measurements 
Protein expression and activation were determined for OA investigations [fig. 2.9]. 
Total and activated eNOS expression was measured by Western blot analysis using 
protocols previously described on section 2.4.4. 
 
Statistical analyses 
All data are expressed as mean ± SEM. Statistical analyses were done with        
Student‟s t-test or one-way ANOVA (with Bonferroni post-hoc test if p<0.05). Data 
displaying a p-value of <0.05 were considered statistically significant. Graph Pad 
Prism ® version 5.01 software was used for all analyses.  
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Chapter 3: Results 
 
3.1 ED induction (model establishment) 
Nitric oxide levels are expressed as mean DAF-2/DA fluorescence intensity or         
% cells that stain positive with DAF-2/DA (% DAF-2/DA fluorescent cells).  
 
3.1.1 Glucose incubation to induce hyperglycaemia 
25 mM glucose incubation for 24 hours 
Mean DAF-2/DA fluorescence intensity increased significantly in glucose treated 
cells when compared to untreated control (control: 100 % vs. glucose: 114.4 ± 5.9 %; 
p = 0.03, n = 9) [fig. 3.1A]. However, % DAF-2/DA fluorescent cells did not differ 
significantly between control and glucose treated samples (control: 100 % vs. 
glucose: 140.5 ± 19.37 %; p = 0.053, n = 9) [fig. 3.1B]. Cell viability was not affected 
by glucose treatment (control: 100 % vs. glucose: 101.1 ± 0.53 %; p > 0.05, n = 9) 
[fig. 3.1C]. 
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Figure 3.1A: (i) Bar graph depicting mean DAF-2/DA fluorescence intensity expressed as percentage 
of control. Glucose vs. control. *: p = 0.03. (ii) A representative histogram showing DAF-2/DA 
fluorescence on the FL1-H axis in control (black) and glucose (pink) treated cells. 
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Figure 3.1B: % DAF-2/DA fluorescent cells expressed as percentage of control. Glucose vs. control.      
p > 0.05 
(i) (ii) 
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Figure 3.1C: Cell viability obtained from FACS analysis of cells excluding PI (i.e. viable cells) and 
expressed as percentage of control. Glucose vs. control, p > 0.05. 
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3.1.2 TNF-α incubation to simulate inflammation 
To simulate inflammation, CMECs were treated with the pro-inflammatory cytokine,    
TNF-α, at 1 ng/ml for 24 hours, 5 ng/ml for 6 hours and 5 ng/ml for 24 hours. 
 
1 ng/ml TNF-α for 24 hours 
At 1 ng/ml (24 hours), TNF-α increased mean DAF-2/DA fluorescence intensity 
significantly by 24 % when compared to control (control: 100 % vs. TNF-α: 124.3 ± 
6.8 %; p = 0.002, n = 10) [fig. 3.2A] and % DAF-2/DA fluorescent cells increased 
significantly by 53.5 % compared to control (control: 100 % vs. TNF-α: 153.5 ± 18.46 
%; p = 0.009, n = 10) [fig. 3.2B]. No significant differences were observed in cell 
viability (control: 100 % vs. TNF-α: 102.3 ± 0.64; p = 0.07, n = 2) [fig. 3.2D]. 
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Figure 3.2A: (i) Mean DAF-2/DA fluorescence intensity expressed as % of control. 1 ng/ml TNF-α vs. 
control (24 hours), *: p = 0.002. (ii) A representative histogram showing DAF-2/DA fluorescence on 
the FL1-H axis in control (black) and TNF-α (blue) treated cells. 
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Figure 3.2B: % DAF-2/DA fluorescent cells expressed as percentage of control. 1 ng/ml TNF-α vs. 
control (24 hours) *: p = 0.009 
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Figure 3.2C: Percentage of viable cells (expressed as % of control) as determined from FACS 
analysis of cells excluding PI. 1 ng/ml TNF-α vs. control (24 hours), p = 0.07. 
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5 ng/ml TNF-α for 6 hours 
A 31 % increase in mean DAF-2/DA fluorescence intensity was observed when 
CMECs were treated with 5 ng/ml for 6 hours (control: 100 % vs. TNF-α: 130.7 ± 9.8 
%; p = 0.04, n = 14) [fig. 3.3A]. % DAF-2/DA fluorescent cells remained unchanged 
(control: 100% vs. TNF-α: 100 ± 1.17 %; p = 0.97, n = 14) [fig. 3.3B]. Cell viability 
was not altered by this intervention (control 100 % vs. TNF- α: 99.5 ± 0.64 %; p = 
0.48,   n = 3) [fig. 3.3C]. 
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Figure 3.3A: (i) Mean DAF-2/DA fluorescence intensity expressed % of control. 5 ng/ml TNF-α vs. 
control (6 hours), *: p = 0.04. (ii) A representative histogram showing DAF-2/DA fluorescence on the 
FL1-H axis in control (black) and TNF-α (blue) treated cells. 
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Figure 3.3B: % DAF-2/DA fluorescent cells expressed as percentage of control. 5 ng/ml TNF-α vs. 
control (6 hours), p = 0.97. 
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Figure 3.3C: Cell viability expressed as percentage of control as determined from cells excluding PI.     
5 ng/ml TNF-α vs. control (6 hours), p = 0.48. 
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5 ng/ml TNF-α for 24 hours 
The model of ED in CMECs was established by incubation with 5 ng/ml TNF-α over 
a period of 24 hours. Mean DAF-2/DA fluorescence intensity decreased by 14.2 % in 
TNF-α treated CMECs when compared to control (control: 100 % vs. TNF-α: 85.80 ± 
2.9 %; p = 0.0001, n = 16) [fig. 3.4A]. % DAF-2/DA fluorescent cells also showed a 
decrease in TNF-α treated cells compared to control (control: 100 % vs. TNF-α: 
88.61 ± 4.42 %; p = 0.02, n = 16) [fig. 3.4B] No statistical significance was observed 
in cell viability between control and TNF-α treated CMECs (control 100 % vs. TNF-α: 
99.31 ± 0.40; p = 0.10, n = 13) [fig. 3.4C] 
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Figure 3.4A:  (i) Mean DAF-2/DA fluorescence intensity expressed % of control. 5 ng/ml TNF-α vs. 
controls (24 hours), *: p = 0.0001. (ii) A representative histogram showing DAF-2/DA fluorescence on 
the FL1-H axis in control (black) and TNF-α (blue) treated cells. 
 
(i) (ii) 
97 
 
Control TNF-
0
25
50
75
100
125
150
*
%
 D
A
F
-2
/D
A
 f
lu
o
re
s
c
e
n
t 
c
e
ll
s
(%
 o
f 
c
o
n
tr
o
l)
 
Figure 3.4B: % DAF-2/DA fluorescence cells expressed as percentage of control. 5 ng/ml TNF-α vs. 
controls (24 hours), *: p = 0.02. 
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Figure 3.4C: Cell viability expressed as percentage of control obtained from FACS analysis of cell 
excluding PI. 5 ng/ml TNF-α vs. controls (24 hours), p = 0.10. 
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3.2 Superoxide measurements 
We measured O2
- levels in our model of ED (5 ng/ml TNF-α treated CMECs for 24 
hours) by FACS analysis of DHE fluorescence. Levels of O2
- are expressed as mean 
DHE fluorescence intensity or % cells that stain positive with DHE (% DHE 
fluorescent cells). There were no significant differences in both mean DHE 
fluorescence intensity (control: 100 % vs. TNF-α: 132 ± 26.6 %; p = 0.24, n = 12) [fig 
3.5A] and % DHE fluorescent cells (control: 100 % vs. TNF-α: 97.7 ± 1.2 %; p = 
0.07, n = 12) [fig 3.5B] when compared to control. 
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Figure 3.5: A: Mean DHE fluorescence intensity expressed as percentage of control. TNF-α vs. 
control, p = 0.24. B: % DHE fluorescent cells expressed as percentage of control. TNF-α vs. control,   
p = 0.07 
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3.3 Protein expression measurements 
All protein expression and phosphorylation measurements were done on our ED 
model (5 ng/ml TNF-α treated CMECs for 24 hours) by Western blotting analysis.  
 
3.3.1 Total eNOS expression and activation  
Total eNOS 
The increases observed in total eNOS expression in TNF-α treated samples did not 
differ significantly compared to control (control: 1 vs TNF-α: 1.70 ± 0.40; p = 0.99, n 
= 8) [fig. 3.6A]. 
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Figure 3.6A: Total eNOS expression in TNF-α vs. control, p = 0.99. β-tubulin shown for verification of 
equal protein loading. 
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Phosphorylated (activated) eNOS Ser 1177 
eNOS phosphorylation decreased significantly by 40 % in TNF-α treated cells when 
compared to control (control: 1 vs TNF-α: 0.60 ± 0.095; p = 0.001, n = 8) [fig. 3.6B] 
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Figure 3.6B: Phosphorylated eNOS levels in TNF-α vs. control, *: p = 0.001. 
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Phospho / total eNOS ratios 
When phosphorylated eNOS was expressed as a ratio of total eNOS, a significant 
decrease of 45 % was observed in TNF-α treated cells (control: 1 vs TNF-α: 0.55 ± 
0.150; p = 0.009, n = 8) [fig. 3.6C]. 
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Figure 3.6C: Phosphorylated eNOS expressed as ratio of total eNOS in TNF-α vs. control, *: p = 
0.009. 
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3.3.2 Total PKB / Akt expression and activation  
Total PKB / Akt expression did not differ significantly between control and TNF-α 
treated cells (control: 1 vs. TNF-α: 1.07 ± 0.058; p =0.198, n = 10) [fig. 3.7A]. 
However, phosphorylated PKB / Akt (Ser 473) levels decreased significantly by 42 % 
in TNF-α treated when compared to control (control: 1 vs. TNF-α: 0.52 ± 0.139; p = 
0.003, n = 10) [fig. 3.7B]. 
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Figure 3.7A: Total PKB / Akt expression in TNF-α vs. control, p = 0.198. 
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Figure 3.7B: Phosphorylated (activated) PKB / Akt Ser 473 in TNF-α vs. control, *: p = 0.003. 
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3.3.3 p22-phox expression 
p22-phox, a membrane-bound subunit of NADPH oxidase was used to quantify 
NADPH oxidase expression. p22-phox increased significantly by 3.2-fold in TNF-α 
treated when compared to control (control: 1 vs. TNF-α: 3.23 ± 0.353; p = 0.0001,    
n = 6) [fig. 3.8]. 
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Figure 3.8: p22-phox expression in TNF-α vs. control, *: p = 0.0001. β-tubulin shown for verification of 
equal protein loading. 
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3.3.4 Nitrotyrosine expression 
Protein nitration in our model of ED was quantified by Western blot analysis of 
nitrotyrosine expression and regarded as a marker for peroxynitrite induced oxidative 
stress. However, there were no significance differences in nitrotyrosine expression 
between control and TNF-α treated cells (control: 1 vs. TNF-α: 0.96 ± 0.041;              
p = 0.38, n = 10) [fig. 3.9]. 
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Figure 3.9: Nitrotyrosine expression in TNF-α vs. control, p = 0.38. 
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3.4 Plant extracts studies  
3.4.1 Pilot studies to assess effects of OA on normal CMECs 
30 µM OA incubation for 5 and 20 min 
30 µM OA increased mean DAF-2/DA fluorescence intensity significantly by 44 % 
after 5 min of incubation (control: 100 % vs. OA: 144.3 ± 13.0; p < 0.0001, n = 9) and 
by 83 % after 20 min of incubation (control 100 % vs. OA: 183.0 ± 14.9; p < 0.0001, 
n = 9) [fig. 3.10A]. The vehicle controls treated with DMSO showed unaltered mean 
DAF-2/DA fluorescence intensity (control: 100 % vs. DMSO: 97.27 ± 7.4 %; p > 0.05, 
n = 17) [fig. 3.10A & 3.10B] and cell viability [fig. 3.10C], and OA had no significant 
effect on cell viability [fig. 3.10C]. 
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Figure 3.10A: Mean DAF-2/DA fluorescence intensity expressed as percentage control. 30 µM OA 5 
min vs. control, *: p < 0.0001 and 30 µM OA 20 min vs. control, : p < 0.0001.   
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Figure 3.10B: A representative histogram showing DAF-2/DA fluorescence in control (black) and OA       
5 min (blue) and OA 20 min (purple) with 30 µM treatment. 
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Figure 3.10C: Stacked bar-chart depicting changes in percentage of non-viable cells (apoptotic and 
necrotic cells) at 30 µM OA incubation for 5 and 20 min. Data expressed as mean ± SEM. p > 0.05 in 
all groups. 
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40 µM OA incubation for 5 and 20 min 
At 40 µM OA, mean DAF-2/DA fluorescence intensity did not increase significantly 
after 5 min incubation (control: 100 % vs. OA: 125.2 ± 24.6 %; p > 0.05, n = 9). 
However, a significant 2.5-fold increase was observed in NO production after 20 min 
OA incubation at this dosage (control: 100 % vs. OA: 246 ± 34.4%, p < 0.0001,         
n = 9) [fig. 3.11A & 3.11B]. OA had no significant effect on cell viability [fig. 3.11C], 
and vehicle controls had no significant effect on either NO production (control: 100 % 
vs. DMSO: 102.8 ± 6.8 %; p > 0.05, n = 17) [fig. 3.11A] or cell viability [fig. 3.11C] 
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Figure 3.11A: Mean DAF-2/DA fluorescence intensity expressed as percentage of control. 40 µM OA 
20 min vs. control, *: p < 0.0001. 
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Figure 3.11B: A representative histogram showing DAF-2/DA fluorescence in control (black) and OA 
20 min (purple) at 40 µM OA treatment. 
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Figure 3.11C: A stacked bar-chart showing changes in percentage of non-viable (apoptotic and 
necrotic) cells at 40 µM incubation for 5 and 20 min. Data expressed as mean ± SEM. p > 0.05 in all 
groups. 
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3.4.2 The effects OA in ED 
3.4.2.1 NO production and viability measurements 
40 µM OA and 5 ng/ml TNF-α for 24 hours 
To investigate the effects of OA in our model of ED, four groups were investigated: 
control, TNF-α treated group, OA group and TNF-α + OA group [fig. 2.9 under 
methods (chapter 2)]. TNF-α (5 ng/ml over 24 hours) induced ED by significantly 
decreasing mean DAF-2/DA fluorescence intensity by ~ 27 % (control: 100 % vs. 
TNF-α: 72.61 ± 5.3 %; p < 0.0001, n = 15) [fig. 3.12A]. No significant differences in 
mean DAF-2/DA fluorescence intensity were observed in the OA group when 
compared to control (control: 100 % vs. OA: 83.88 ± 8.1; p > 0.05, n = 9). However, 
pre-treatment of CMECs with OA before ED induction (TNF-α + OA group) 
significantly increased mean DAF-2/DA fluorescence intensity back to control levels 
when compared to the TNF-α only group (TNF-α: 72.61 ± 5.3 % vs. TNF-α + OA: 
98.45 ± 10.9; p < 0.0001, n = 9) [fig. 3.12A & 3.12B]. Cell viability did not differ 
significantly in TNF-α, OA and TNF-α + OA groups when compared to control. 
However, pre-treatment with 40 µM OA significantly reversed the necrotic and 
apoptotic effects of TNF-α (PI: TNF-α 2.2 ± 0.4 % vs. TNF-α + OA: 0.6 ± 0.1 %; p < 
0.05, n = 6 and annexin V: TNF-α: 6.0 ± 1.3 % vs. TNF-α + OA: 0.8 ± 0.1 %; p < 
0.05, n = 6) respectively [fig. 3.12C & 3.13]. Separate investigations showed that 
DMSO alone (vehicle control for OA) had no effect on either DAF-2/DA fluorescence 
or cell viability (data not shown).  
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Figure 3.12A: Mean DAF-2/DA fluorescence intensity expressed as percentage of control. TNF-α vs. 
control, *: p < 0.0001 and TNF-α + 40 µM OA vs. TNF-α, : p < 0.0001 
 
Figure 3.12B: A representative histogram showing DAF-2/DA fluorescence on the FL1-H axis in TNF-
α (blue) and TNF-α + 40 µM OA (green). 
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Figure 3.12C: A stacked bar chart showing the percentage of non-viable (apoptotic and necrotic) cells 
treated with 5 ng/ml TNF-α and / or 40 µM OA (24 hours). *: p < 0.05 TNF-α vs. TNF-α + OA. 
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Figure 3.13: Representative dot plots showing PI and annexin V fluorescence in cells treated with 5 
ng/ml TNF-α with or without 40 µM OA pre-treament (24 hours). A: Treatment of CMECs with TNF-α 
resulted in a 9.6 % incidence of apoptosis (annexin V positive cells) 3.6 % necrosis (PI positive cells). 
B: Pre-treatment with 40 µM OA significantly reversed the apoptotic and necrotic effects of TNF-α to 
0.5 and 0.4 % respectively. Treatment with OA therefore increased % viable cells from 86.7 to 98.6 
%. 
A 
B 
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3.4.2.2 Cellular mechanisms of OA on CMECs and ED model 
Total eNOS expression and phosphorylated (activated) eNOS 
40 µM OA and 5 ng/ml TNF-α for 24 hours 
Following our investigations into the effects of OA on NO production in normal and 
dysfunctional CMECs, we investigated the cellular mechanisms involved using the 
40 µM dosage of OA. Our groups consisted of the non-treated control, vehicle 
control treated with DMSO only, ED group (5 ng/ml TNF-α over 24 hours), OA group 
and TNF-α + OA treated group. We found no significant differences in total eNOS 
expression and phosphorylated eNOS when comparing all our experimental groups. 
However, when phosphorylated eNOS was expressed as the ratio of total eNOS and 
equal protein loading was adjusted for, the following significant changes were 
observed [fig. 3.14]:  
 eNOS phosphorylation / total ratio increased significantly in the OA treated 
group when compared to control (control: 1 vs. OA: 1.90 ± 0.13; p < 0.05, n = 
3). 
 eNOS phosphorylation / total ratio increased significantly in the TNF-α + OA 
treated group when compared to TNF-α (ED) group (TNF-α + OA: 1.4 ± 0.29 
vs. TNF-α: 0.54 ± 0.15; p < 0.05, n = 3). 
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Figure 3.14: Phosphorylated eNOS expressed as a ratio of total eNOS expression. : p < 0.05 OA vs. 
Control and $: p < 0.05 TNF-α + OA vs. TNF-α. 
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Chapter 4: Discussion 
 
4.1 Summary of results 
4.1.1 The development and establishment of an in vitro model of ED 
In this study, we regarded reduced intracellular NO production as the primary end 
point to identify the development of ED in our model of CMECs. The following known 
inducers of ED were tested: 
 Hyperglycaemia: 25 mM glucose (24 hours) resulted in an increase in NO 
production [fig. 3.1A]. 
 Inflammation: TNF-α 1 ng/ml (24 hours) increased NO production [fig. 3.2A]. 
  TNF-α 5 ng/ml (6 hours) increased NO production [fig. 3.3A]. 
  TNF-α 5 ng/ml (24 hours) decreased NO production [fig.3.4A]. 
Viability data showed that none of the above interventions affected cell viability. 
Based on the above, a model of ED was thus established (i.e. reduced intracellular 
NO production) when CMECs were incubated with 5 ng/ml TNF-α for 24 hours. 
 
4.1.2 Exploration of cellular mechanisms in the TNF-α induced model of ED 
1. eNOS (main source of NO in  endothelial cells):  
 Total eNOS expression remained at control levels [fig. 3.6A]. 
 Phosphorylated eNOS was reduced [fig. 3.6B]. 
 Total / phospho eNOS ratios were decreased [fig. 3.6C]. 
2. PKB / Akt (main upstream activator of eNOS by phosphorylation of residue Ser 
1177): 
 Total PKB / Akt expression remained at control levels [fig. 3.7A]. 
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 Phosphorylated PKB / Akt was reduced [fig. 3.7B]. 
3. O2
- production (marker of cellular oxidative stress) remained unchanged [fig. 3.5].  
4. p22-phox expression (subunit of O2
- producing NADPH oxidase) was increased 
[fig. 3.8].  
5. Nitrotyrosine expression (marker of peroxynitrite induced protein nitration) 
remained at control levels [fig. 3.9]. 
 
4.1.3 Effects of OA on CMECs and ED 
1. Our investigations into the effects of OA in control CMECs showed the following: 
 30 µM OA increased NO levels after 5 and 20 minutes of incubation [fig. 
3.10A]. 
 40 µM OA only increased after 20 minutes incubation [fig. 3.11A]. 
 Cell viability was not affected with either 30 µM or 40 µM treatments. 
2. Investigations into the effects of OA in ED (TNF-α induced model) showed that 
pre-treatment with 40 µM OA reversed ED [fig. 3.12A]. Furthermore 40 µM OA 
reversed the pro-apoptotic and necrotic effects of TNF-α in our ED model [fig. 
3.12C].  
3. OA significantly increased eNOS phosphorylation in normal CMECs and 
pretreatment with 40 µM OA significantly restored eNOS phosphorylation back to 
control levels in TNF-α treated cells [fig. 3.14] 
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4.2 Discussion of results  
4.2.1 ED model 
In the first part of this study, we primarily aimed to (i) establish a model of ED in 
CMECs obtained from myocardial capillaries, and (ii) to investigate cellular 
mechanism associated with ED in CMECs. Unlike other endothelial cells, CMECs 
derived from myocardial capillaries possess a special attribute in that they are 
situated in blood vessels that do not dilate or constrict due the absence of smooth 
muscle layer (Strijdom & Lochner 2009). In view of this, ED in the myocardial 
capillaries will not result in a deficient NO-dependent vasodilatory response as 
observed in larger, smooth muscle containing vessels. Rather, due to their uniquely 
positioned setting in close proximity to cardiomyocytes, dysfunction of CMECs would 
potentially have implications on myocardial contractile function. Very few studies 
have investigated ED in endothelial cells derived from myocardial capillaries, and the 
present study aims to address this gap in the literature. 
 
The association between diabetes and cardiovascular disease is indisputable 
(Soldatos et al 2005), and hyperglycaemia is a common feature of diabetes amongst 
other metabolic disorders (Potenza et al 2009). Both acute and chronic 
hyperglycaemia is implicated in endothelial damage; in fact, ED triggers micro- and 
macrovascular complications such as renal failure, blindness, and atherosclerosis 
associated with diabetes (Potenza et al 2009). Mechanisms of hyperglycaemia 
induced-ED include oxidative stress, increased formation AGEs and increased 
activity of PKC, all of which result in decreased NO bioavailability (Guzik et al 2002; 
Avogaro et al 2008). Inflammation is now recognised as both an independent risk 
factor and an underlying mechanism of ED (Libby et al 2002). Inflammation is often 
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associated with increased circulating levels of inflammatory cytokines such as TNF-
α, which directly cause ED via enhancing oxidative stress and downregulation of 
eNOS expression (Zhang et al 2009; Valerio et al 2006). In order to establish a 
model of ED in CMECs, we therefore mimicked a hyperglycaemic and pro-
inflammatory state by treatment with glucose (high concentration) and TNF-α 
respectively.  
 
 
Our experimental model of ED was successfully achieved with treatment of CMECs 
with the pro-inflammatory cytokine TNF-α (5 ng/ml for 24 hours). Previous studies on 
endothelial cells derived from larger vessels have implicated TNF-α in the induction 
of ED. Possible mechanisms of TNF-α induced ED include increased O2
- generation 
by NADPH or xanthine oxidase (Gao et al 2007; Picchi et al 2006) or downregulation 
of eNOS mRNA expression (Zhang et al 2009; Valerio et al 2006; Lai et al 2003). In 
this study, ED induction with TNF-α appeared to be dose and time dependent. Our 
data showed that 1 ng/ml (lower dosage) incubation for 24 hours and 5 ng/ml for 6 
hours (shorter incubation period) did not induce ED. Gupta and Khandelwal (2004) 
showed that 1 ng/ml TNF-α over 24 hours favoured an increase in PKB / Akt 
phosphorylation in HepG2 cells. It is a known fact that PKB / Akt is an upstream 
activator of eNOS by phosphorylation of Ser 1177 residue thus leading to increased 
NO production. This may explain the rise in NO levels observed in our study with      
1 ng/ml TNF-α treatment. De Palma et al (2006) demonstrated a time dependent 
increase in eNOS activation in human endothelial cells, peaking at 6 hours following 
TNF-α treatment. This may explain the rise in NO levels observed with 5 ng/ml TNF-
α treatment over the shorter incubation time of 6 hours in our model. 
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Treatment with a high dosage of glucose also did not induce ED in our model of 
CMECs; in fact we observed a significant increase in NO production. These findings 
agree with those of Cosentino et al (1997), who also reported an increase in eNOS 
gene expression and NO production paralleled by an increase in O2
- in human aortic 
endothelial cells following treatment high dosage (22.2 mM) of glucose over 5 days. 
We did not measure O2
- in our glucose treated CMECs and follow-up studies could 
verify whether our model also exhibited oxidative stress. On the other hand, others 
showed a downregulation of eNOS activity in bovine aortic endothelial cells treated 
with 30 mM glucose for 48 hours (Du et al 2001). Endothelial cell heterogeneity, 
different dosages and incubation times may explain the discrepancies observed in 
these variable findings with glucose.  
 
4.2.2 Cellular mechanisms of TNF-α induced ED in our model: eNOS and PKB / 
Akt expression and activation 
In our attempts to explore cellular mechanisms of decreased NO production in TNF-
α treated CMECs, we investigated the expression and activity of the main source of 
NO in endothelial cells. Activity of eNOS is dependent on factors such as 
dimerisation, displacement from caveolin-1 and phosphorylation at Ser 1177 
(Forstermann & Munzel 2006; Dudzinski & Michel 2007). According to the literature, 
TNF-α can induce ED by upregulating NADPH or xanthine oxidase leading to 
oxidative stress and hence NO scavenging (Gao et al 2007; Picchi et al 2006), and/ 
or by accelerating eNOS mRNA degradation thus leading to a decrease in total 
eNOS protein expression (Zhang et al 2009; Valerio et al 2006; Lai et al 2003). 
Contrary to the latter findings, our data showed that total eNOS expression remained 
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unchanged. Phosphorylated (activated) eNOS as well as phospho eNOS / total 
eNOS ratios were however, significantly decreased in our ED model, which could 
explain the lower NO production observed.  
 
PKB / Akt is a known upstream activator of eNOS by phosphorylation of Ser 1177, 
however, activity of PKB / Akt is dependent on phosphorylation of its residue Ser 473 
by PI-3K (Strijdom et al 2009 (a)). Our data showed that total PKB / Akt expression 
remained at control levels, but phosphorylated (activated) PKB / Akt decreased 
significantly in our ED model. These findings suggest that reduced activation of the 
PKB / Akt-eNOS pathway may be the primary mechanistic pathway of ED in our 
model of CMECs. eNOS uncoupling and decreased eNOS expression are often the 
proposed mechanisms of ED in the literature. Though the activity of the PKB / Akt –
eNOS pathway is a critical determinant of NO production, it is often overlooked in the 
context of ED. We have therefore, for the first time as far as we are aware, 
demonstrated reduced activation of the PKB / Akt-eNOS as the primary mechanistic 
pathway of ED in an in vitro model of ED in myocardial capillary-derived CMECs.   
 
4.2.3 Cellular mechanisms of TNF-α induced ED in our model: Superoxide 
levels, p22-phox and nitrotyrosine expression (oxidative stress) 
The data from most studies on ED seem to demonstrate that cellular oxidative stress 
is an important contributing factor (and a consequence) of ED (Gao et al 2007). 
Although the first part of the current study clearly showed reduced activation of the 
PKB / Akt-eNOS pathway as a principal mechanism of ED in our model, we went 
further to explore whether oxidative stress was also involved. To this end, we 
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measured three independent markers of oxidative stress, namely (i) p22-phox 
expression, (ii) intracellular O2
- levels, and (iii) nitrotyrosine expression.  
 
Overproduction of O2
- is a common link between cardiovascular risk factors (such as 
diabetes mellitus, smoking, and hypertension) and ED. Furthermore, over-
expression of the pro-inflammatory cytokine, TNF-α, has been associated with 
oxidative stress (Gao et al 2007; Li J-M et al 2002). We therefore measured O2
- 
production in our ED model by FACS analysis of the O2
- sensitive probe, DHE. We 
however, did not observe any significant changes in O2
- levels with this probe in our 
ED model. Contrary to this finding, protein expression studies demonstrated a 
significantly higher p22-phox expression in our ED model, suggesting an over-
expression of NADPH oxidase enzyme, the major source of O2
- in the vascular 
system (Griendling et al 2000). Indeed, TNF-α has been reported to promote 
oxidative stress via over expression of NADPH oxidase (Picchi et al 2006; Gao et al 
2007). Consistent with our finding, De Keulenaer et al (1998) reported an increase in 
p22-phox expression in VSMCs in response to TNF-α treatment. According to 
Djordjevic et al (2005), an increase in p22-phox expression was associated with a 
delayed increase in ROS generation in endothelial cells. This may explain the 
contradiction observed in O2
- levels and p22-phox expression in our study. Despite 
not observing an increase in O2
- levels as measured by DHE, the convincing 
increase in p22-phox expression does serve as strong indication that our ED model 
is, at least in part, associated with oxidative stress. The failure of the probe to 
demonstrate increased O2
- levels could also be ascribed to the fact an initial burst of 
O2
- might have rapidly been cancelled by the scavenging actions of molecules such 
as SOD and NO by the time the probe was added. 
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Nitrotyrosine expression is a useful indirect marker of increased peroxynitrite 
production (Ceriello et al 2001) and high levels of peroxynitrite are associated with 
the induction of eNOS uncoupling (Zou et al 2002 (a); Kuzkaya et al 2003). 
Nitrotyrosine expression remained at control levels in our ED model. High levels of 
peroxynitrite are said to be a product of increased rates between NO and O2
-. 
Though there was an increase in NADPH oxidase expression, NO production was 
decreased in our ED model. In view of the decreased PKB / Akt-eNOS activation 
pathway in our ED model, we speculate that the amounts of available NO were 
presumably not sufficient to result in formation of peroxynitrite levels high enough to 
trigger enhanced protein nitration and hence increased nitrotyrosine expression in 
our ED model. Furthermore, according to Pacher et al (2007), peroxynitrite reacts at 
a slow rate with biological compounds and thus our 24 hour incubation may have 
been too short for enhanced protein nitration to occur. 
 
4.2.4 Effects of OA on CMECs 
In the second part of the study, we aimed to investigate the effects of Syzigium 
Cordatum leaf extract-derived OA on our normal and dysfunctional CMECs. OA is a 
bioactive triterpenoid that has also been isolated from plants such as Olea europaea 
(olive oil) and Radix ginseng, known to have beneficial properties (Xi et al 2009; Sato 
et al 2007). Literature demonstrates OA to have anti-inflammatory, anti-hypertensive, 
and hypoglycaemic properties (Musabayane et al 2005; Mapanga et al 2009). 
Furthermore, OA has previously been reported to induce NO-dependent vasodilation 
in macrovascular endothelial cells (Rodriguez-Rodriguez et al 2008).  
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To our knowledge the effects of OA on NO production have not previously been 
investigated in myocardial capillary-derived CMECs. In a study by Rodriguez-
Rodriguez et al (2008), OA resulted in a dose dependent increase in NO production 
in rat mesenteric arteries, with the highest increase in NO obtained at 30 µM OA 
concentration. Our investigations revealed that 30 µM of OA led to significantly 
increased NO levels (43 % after 5 min and 83 % after 20 min of incubation), whereas 
40 µM OA increased NO production by 2.5-fold after 20 min, but had no significant 
effect after 5 min. In view of the considerable increase in NO production evoked by 
the 40 µM OA in our model of CMECs after 20 min, this dosage was used for further 
investigations.  
 
4.2.5 Effects of OA on ED 
Following the promising data observed with OA in normal CMECs, we undertook 
investigations to explore whether OA could reverse NO-lowering effects of TNF-α in 
our ED model. Several studies have reported OA to have anti-hypertensive, 
hypoglycaemic (Mapanga et al 2009) and hypolipidaemic properties (Liu et al 2007). 
Furthermore, OA is a component of the food substances such as olive oil that has 
been reported to have beneficial effects on the cardiovascular system (Rodriguez-
Rodriguez et al 2008). For example, long-term intake of pomace olive oil 
supplemented with or without OA has been reported to enhance endothelial function 
in spontaneously hypertensive rats by enhancing eNOS expression and pomace 
olive oil is said to naturally have a high content of OA (Rodriguez-Rodriguez et al 
2007). Though its putative vasorelaxant properties by enhancing either PGI2 or NO 
production have been shown in several studies (Martinez-Gonzalez et al 2008; 
Rodriguez-Rodriguez et al 2008), the effects of OA in ED remain unclear. In this 
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study, we investigated the effects of OA using the 40 µM dosage, and our data 
showed that OA significantly reversed ED by restoring NO production back to control 
levels.  
 
TNF-α has previously been associated with endothelial cell apoptosis (Deshpande et 
al 2000). Furthermore, TNF-α has also been shown to initiate ROS-dependent 
necrotic cell death (Morgan et al 2008). Albeit not significant, treatment with TNF-α 
induced some degree of apoptosis and necrosis in our model of CMECs. However, 
OA significantly reversed the pro-necrotic and pro-apoptotic effects of TNF-α thus 
restoring cell viability to control levels.  
 
4.2.6 Cellular mechanisms of OA in CMECs and ED model 
To determine the cellular mechanistic pathway of OA, we measured the expression 
and activation of the main source of NO in the endothelial cells, eNOS. When 
expressed as a ratio of total eNOS and following correction of equal protein loading, 
eNOS phosphorylation (activation) increased significantly in the OA group, when 
compared to the control group. Furthermore pretreatment with 40 µM OA restored 
eNOS activity in the TNF-α treated samples. Rodriguez-Rodriguez et al (2008) 
reported a rapid increase in eNOS phosphorylation Ser 1177 in response to OA 
treatment in human umblical vein endothelial cells. Phosphorylation was inhibited by 
PI3-K inhibitors suggesting PKB / Akt as the main key player of OA-induced eNOS 
phosphorylation in their study. From our observations and that of Rodriguez-
Rodriguez et al 2008, it appears that OA stimulates the activity of the PKB / Akt- 
eNOS pathway thus leading to an increase in NO production. Others have also 
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reported OA to increase the expression of eNOS (Rodriguez-Rodriguez et al 2007). 
We however, found no changes in expression of eNOS.  
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Chapter 5: Conclusion 
 
5.1 Conclusions 
To date, there is very little information on ED in myocardial capillary derived 
endothelial cells / CMECs. The importance of the endothelium is now well 
appreciated; however, its structural and functional heterogeneity is often overlooked 
especially in the context of ED. For the first time, as far as we are aware, we have 
established an experimental model of ED in this functionally unique endothelial cell 
type. We have also demonstrated a novel, though surprisingly obvious, cellular 
mechanistic pathway of ED (reduced PKB / Akt-eNOS activation). The marked 
increase in p22-phox expression suggests that a degree of eNOS uncoupling might 
have been present, which could serve as an additional mechanism of ED in our TNF-
α induced ED model. However, in view of the unchanged nitrotyrosine expression in 
our model and inability to demonstrate increased O2
- levels, we propose that the 
decrease in the activity of PKB / Akt-eNOS pathway (thus leading to reduced NO 
production) was the primary mechanistic pathway of ED in our model (Fig. 5.1).  For 
a summary of our findings, refer to table 5.1 
 
Consistent with previous findings on macrovascular endothelial cells, OA appears to 
have NO production stimulatory effects in our model of CMECs. We also 
demonstrate the ability of OA to reverse ED by restoring NO production. OA appears 
to confer protective effects on our model of CMECs, as demonstrated by the ability 
of OA to reverse the pro-apoptotic and pro-necrotic effects of TNF-α. From our 
observations, the NO production stimulatory effects of OA are most likely mediated 
by the activation of the PKB / Akt-eNOS pathway. Our data therefore adds further 
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validation to the notion that OA represents a novel therapeutic tool in enhancing 
endothelial function and hence cardiovascular health.   
 
5.2 Shortcomings of the study 
Superoxide levels in ED cells: Our DHE fluorescence data were inconclusive and did 
not support the p22-phox results. We believe this could probably be due to technical 
considerations related to probe and time of incubation. We plan to expand our 
superoxide measurement studies with DHE (using at different time points) and to 
incorporate other possible superoxide measurement methods. 
 
PKB / Akt, p22-phox and nitrotyrosine in OA treated samples: Due to time 
constraints and technical glitches, we were unable to complete Western blot 
analyses of these proteins in the OA experiments. Results from these studies would 
have given valuable insight into the mechanisms of OA, follow-up investigations to 
adress this will be undertaken shortly.  
 
5.3 Future direction 
Investigations on CMECs-to-cardiomyocyte interaction in the setting of ED and thus 
establishment of an in vitro coculture model of dysfunctional CMEC-cardiomyocyte 
are necessary to provide more insight on relevance of ED in myocardial derived 
CMECs.  
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Parameter Decreased Increased No change 
NO production √   
eNOS activation √   
PKB / Akt activation √   
Superoxide production   √ 
P22-phox expression  √  
Nitrotyrosine expression   √ 
 
Table 5.1: A summary of our findings during establishment of an experimental model of ED (5 ng/ml 
TNF-α for 24 hours). 
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Figure 5.1: Proposed mechanisms of ED and OA in our model of CMECs.  
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